Data / Research funding / Sexually Transmitted Infections
Sexually Transmitted Infections: 1,344 NIH awards ($2.1B) to 328 organizations
1,344 NIH awards ($2.1B) in the NIH spending category Sexually Transmitted Infections, to 328 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 1,344 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| HIV Prevention Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $213,590,410 | June 1, 2006 | November 30, 2027 | COHEN, MYRON SCOTT | reporter.nih.gov |
| Pediatric HIV/AIDS Cohort Study (PHACS) 2020 | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $71,153,847 | September 18, 2020 | July 31, 2026 | WILLIAMS, PAIGE L | reporter.nih.gov |
| Cancer Center Support Grant (CCSG) | NIH | National Cancer Institute | 2021 to 2025 | $35,080,297 | April 1, 1997 | February 28, 2026 | ROBERTS, CHARLES | reporter.nih.gov |
| FOLLOW-UP AND EXTENDED FOLLOW-UP OF PARTICIPANTS | NIH | National Cancer Institute | 2021 to 2025 | $29,487,084 | April 6, 2018 | September 15, 2026 | PORRAS, CAROLINA | reporter.nih.gov |
| Case Comprehensive Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $28,812,474 | August 1, 1997 | March 31, 2030 | SCHWARTZ, GARY K | reporter.nih.gov |
| UZ-UCSF CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,624,239 | September 9, 2025 | November 30, 2027 | CHIRENJE, ZVAVAHERA MIKE | reporter.nih.gov |
| Vaccine and Treatment Evaluation Unit at Saint Louis University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,219,564 | December 11, 2019 | November 30, 2026 | HOFT, DANIEL F. | reporter.nih.gov |
| Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $21,023,937 | April 1, 2019 | September 30, 2026 | SHARMA, ANJALI | reporter.nih.gov |
| Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $19,528,719 | June 1, 1997 | June 30, 2028 | STEIDL, ULRICH | reporter.nih.gov |
| Cancer Center Support Grant P30 | NIH | National Cancer Institute | 2021 to 2025 | $17,994,069 | July 1, 2002 | June 30, 2026 | LARA, PRIMO N. | reporter.nih.gov |
| University of Washington Vaccine and Treatment Evaluation Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,173,751 | December 11, 2019 | November 30, 2026 | WALD, ANNA | reporter.nih.gov |
| Pitt-Ohio State Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,065,770 | February 1, 2007 | November 30, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| RADXHIV VIRAL LOAD | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2025 | $12,723,739 | September 11, 2007 | July 31, 2028 | MANABE, YUKARI C | reporter.nih.gov |
| Using Longitudinal Research to Engage African American and Latinx Sexual- and Gender-Minority Youth in the HIV Prevention and Care Continua and Reduce HIV/AIDS-Related Disparities | NIH | National Institute on Drug Abuse | 2021 to 2024 | $11,452,208 | August 15, 2015 | June 30, 2025 | KIPKE, MICHELE D. | reporter.nih.gov |
| Administrative Supplement for the NCI P30 CCSG to extend partnerships with comprehensive cancer control coalitions to study implementation of evidence-based cancer control interventions | NIH | National Cancer Institute | 2021 | $11,079,774 | January 1, 1997 | March 31, 2022 | LYNCH, THOMAS JAMES | reporter.nih.gov |
| Addressing risk through Community Treatment for Infectious disease and Opioid use disorder Now (ACTION) among justice-involved populations | NIH | National Institute on Drug Abuse | 2021 to 2025 | $10,550,278 | September 30, 2020 | July 31, 2026 | SPRINGER, SANDRA ANN | reporter.nih.gov |
| Thailand HIV/AIDS and Infectious Disease Clinical Trials Unit (THAI CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,070,868 | March 15, 2007 | November 30, 2027 | SUPPARATPINYO, KHUANCHAI | reporter.nih.gov |
| Yale Head and Neck Cancer SPORE: Overcoming Treatment Resistance in Head and Neck Cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $9,412,704 | September 22, 2020 | June 30, 2026 | BURTNESS, BARBARA | reporter.nih.gov |
| San Francisco Bay Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,314,128 | March 2, 2007 | November 30, 2027 | BUCHBINDER, SUSAN | reporter.nih.gov |
| Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $8,076,617 | July 15, 2022 | July 14, 2023 | SILVERA, PETER | reporter.nih.gov |
| MSM and Substances Cohort at UCLA Linking Infections Noting Effects (MASCULINE) | NIH | National Institute on Drug Abuse | 2021 to 2024 | $7,177,379 | September 30, 2013 | April 30, 2026 | GORBACH, PAMINA MAE | reporter.nih.gov |
| Increasing financial and health equity among low income black youth and young adults | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $6,783,115 | September 23, 2021 | April 30, 2027 | LIPPMAN, SHERI ANN | reporter.nih.gov |
| Aurum Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,678,965 | December 1, 2020 | November 30, 2027 | CHURCHYARD, GAVIN JOHN | reporter.nih.gov |
| A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,678,063 | May 1, 2019 | April 30, 2025 | RADOLF, JUSTIN D | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,612,767 | September 21, 2022 | January 18, 2026 | KRUISWIJK, CORINE | reporter.nih.gov |
| California-Mexico-Puerto Rico Partnership (CAMPO) Center for Prevention of HPV-related Cancer in HIV+ Populations | NIH | National Cancer Institute | 2021 to 2025 | $6,605,241 | September 12, 2019 | July 31, 2026 | PALEFSKY, JOEL MICHAEL | reporter.nih.gov |
| Comparative Modeling to Inform Cervical Cancer Control Policies | NIH | National Cancer Institute | 2021 to 2024 | $6,568,988 | September 8, 2020 | August 31, 2025 | KIM, JANE JOOYUN | reporter.nih.gov |
| Stellenbosch University Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,524,563 | April 15, 2007 | November 30, 2027 | HESSELING, ANNEKE CATHARINA | reporter.nih.gov |
| Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations (METRICS) | NIH | National Cancer Institute | 2021 to 2023 | $6,487,883 | April 10, 2018 | March 31, 2025 | HUGHES, AMY E | reporter.nih.gov |
| University of Washington (UW) Sexually Transmitted Infections (STI) Cooperative Research Center (CRC) - Syphilis Vaccine to Protect against Local and Disseminated T. pallidum Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $6,406,743 | August 1, 2019 | July 31, 2025 | WALD, ANNA | reporter.nih.gov |
| Partnership for Prevention of HPV-Associated Cancers in People Living with HIV: Brazil, Mexico, and Puerto Rico | NIH | National Cancer Institute | 2021 to 2025 | $5,948,066 | September 20, 2019 | July 31, 2026 | ELLSWORTH, GRANT B. | reporter.nih.gov |
| Cervical, Anal & Oral HPV Persistence/Adolescent Girls | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,549,203 | May 15, 2007 | January 31, 2028 | DIAZ, ANGELA | reporter.nih.gov |
| Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,430,840 | April 12, 2019 | March 31, 2025 | LUETKEMEYER, ANNE FREY | reporter.nih.gov |
| #4Corners4Health: A Social Media Cancer Prevention Program for Rural Emerging Adults | NIH | National Cancer Institute | 2022 to 2025 | $5,181,703 | September 8, 2022 | August 31, 2027 | BULLER, DAVID B | reporter.nih.gov |
| Identification of the Initial Targets of Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,125,048 | July 1, 2022 | June 30, 2027 | HOPE, THOMAS | reporter.nih.gov |
| Microbial Impact on NeuroDegeneration in Alzheimer's Dementia: MIND-AD | NIH | National Institute on Aging | 2021 to 2025 | $5,121,493 | September 30, 2021 | May 31, 2027 | SPIRA, ADAM PETER | reporter.nih.gov |
| Sialic acid analogs against multidrug-resistant gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,099,184 | April 20, 2021 | March 31, 2027 | RAM, SANJAY | reporter.nih.gov |
| Task 12: Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,969,800 | September 6, 2019 | June 30, 2026 | HOOK, EDWARD | reporter.nih.gov |
| Mechanisms of human papillomavirus entry | NIH | National Cancer Institute | 2021 to 2025 | $4,915,530 | August 17, 2020 | July 31, 2027 | DIMAIO, DANIEL C. | reporter.nih.gov |
| Nen ?nkUmbi/EdaHiYedo Plus (NE+): a multi-level intervention to reduce health disparities among American Indian youth | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $4,734,798 | April 1, 2018 | June 30, 2029 | RINK, ELIZABETH LYNNE | reporter.nih.gov |
| A Global Syphilis Vaccine Targeting Outer Membrane Proteins of Treponema pallidum | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $4,663,782 | April 22, 2024 | March 31, 2029 | MOODY, MICHAEL ANTHONY | reporter.nih.gov |
| The UNC/Emory Center for Innovative Technology (iTech) across the prevention and care continuum | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $4,640,955 | September 30, 2016 | November 30, 2022 | HIGHTOW-WEIDMAN, LISA B | reporter.nih.gov |
| New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,603,680 | September 5, 2019 | August 31, 2025 | DAIGLE, DENIS MARC | reporter.nih.gov |
| Defining Drivers of HPV-associated Carcinogenesis | NIH | National Cancer Institute | 2021 to 2025 | $4,601,591 | August 1, 2017 | July 31, 2031 | LAMBERT, PAUL F. | reporter.nih.gov |
| Cytotoxic T Cell Mediated Immunity to Chlamydia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,482,401 | July 1, 1996 | July 31, 2026 | STARNBACH, MICHAEL N | reporter.nih.gov |
| Impact of a novel HIV peer navigationand overdose prevention intervention on engagement in the HIV prevention and treatment cascade. | NIH | National Institute on Drug Abuse | 2021 to 2025 | $4,391,293 | September 1, 2021 | June 30, 2027 | SHERMAN, SUSAN G. | reporter.nih.gov |
| An oral vaccine against Chlamydia trachomatis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $4,358,977 | April 19, 2024 | March 31, 2029 | ZHONG, GUANGMING | reporter.nih.gov |
| Alleviation of ER stress as a translational strategy to curb ocular viral infections | NIH | National Eye Institute | 2022 to 2025 | $4,325,995 | March 1, 2022 | December 31, 2026 | SHUKLA, DEEPAK | reporter.nih.gov |
| The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors | NIH | National Cancer Institute | 2021 to 2025 | $4,277,018 | September 1, 2021 | August 31, 2027 | SIGEL, KEITH MAGNUS | reporter.nih.gov |
| CAMELLIA Cohort: A longitudinal study to understand sexual health and prevention among women in Alabama | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $4,046,847 | September 8, 2022 | August 31, 2027 | RANA, AADIA | reporter.nih.gov |
| A personalized approach using hypoxia resolution to guide curative-intent radiation dose reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers | NIH | National Cancer Institute | 2021 to 2025 | $4,028,888 | March 3, 2020 | March 31, 2030 | LEE, NANCY Y | reporter.nih.gov |
| Nucleoside-modified mRNA vaccine for prevention and treatment of genital herpes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,009,506 | April 15, 2019 | June 30, 2027 | FRIEDMAN, HARVEY MICHAEL | reporter.nih.gov |
| Revealing the roles of HSV1 lytic and latent transcripts in AD pathogenesis and therapy | NIH | National Institute on Aging | 2021 to 2025 | $3,988,565 | September 1, 2021 | May 31, 2026 | ROSENFELD, MICHAEL G | reporter.nih.gov |
| Neisseria gonorrhoeae exploits host interferon epsilon to establish infection in the female urogenital tract | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,970,913 | July 1, 2021 | June 30, 2027 | GOLENBOCK, DOUGLAS T | reporter.nih.gov |
| Explore roles of HSV-1 in Alzheimer's disease using mouse models | NIH | National Institute on Aging | 2021 to 2025 | $3,945,285 | September 30, 2021 | May 31, 2027 | CHEN, CASEY | reporter.nih.gov |
| ReMARk: A multi-level strategy to address disparities in rural HPV-related cancer prevention | NIH | National Cancer Institute | 2022 to 2025 | $3,944,859 | September 22, 2022 | August 31, 2028 | STARAS, STEPHANIE A S | reporter.nih.gov |
| Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,773 | July 1, 2021 | April 30, 2027 | DUNCAN, JOSEPH A | reporter.nih.gov |
| Influence of HIV infection on vaginal virome and risk of preterm birth in pregnant South African women | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,895,544 | September 9, 2021 | July 31, 2027 | JASPAN, HEATHER BERYL | reporter.nih.gov |
| Development of a recombinant protein vaccine for Chlamydia trachomatis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,885,058 | May 10, 2024 | March 31, 2029 | DARVILLE, TONI | reporter.nih.gov |
| Intersection of HSV-1 and microglial genetics in AD | NIH | National Institute on Aging | 2021 to 2025 | $3,846,784 | September 30, 2021 | May 31, 2027 | BRADSHAW, ELIZABETH M | reporter.nih.gov |
| A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV Transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,844,108 | July 23, 2020 | June 30, 2025 | SACHA, JONAH B. | reporter.nih.gov |
| The Effectiveness of Automated Multimodal Imaging in High Grade Squamous Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV: An International Trial | NIH | National Cancer Institute | 2021 to 2025 | $3,831,300 | December 18, 2018 | August 31, 2029 | ANANDASABAPATHY, SHARMILA | reporter.nih.gov |
| Expanding the potential of couples HIV testing: Adjunct modules to reduce drug use among vulnerable male couples | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,790,611 | July 15, 2020 | May 31, 2026 | STARKS, TYREL J | reporter.nih.gov |
| Integrating genomics and the protein interactome for HPV+ head and neck cancer therapy | NIH | National Cancer Institute | 2021 to 2024 | $3,779,781 | August 15, 2018 | July 31, 2025 | GRANDIS, JENNIFER RUBIN | reporter.nih.gov |
| Ultra-Long-Acting Polymeric Injectable Multi-Purpose Prevention Technology for Contraception and HIV Prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,740,241 | April 13, 2021 | March 31, 2027 | BENHABBOUR, SOUMYA RAHIMA | reporter.nih.gov |
| An Etonogestrel/Ethinyl Estradiol/QGriffithsin (ETG/EE/QGRFT) IVR to Prevent Pregnancy and HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,644,121 | April 6, 2020 | August 31, 2025 | TELESHOVA, NATALIA | reporter.nih.gov |
| Novel pre-coital, non-hormonal multipurpose prevention technology (MPT) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,585,858 | March 20, 2020 | February 28, 2026 | ANGSANTIKUL, PAVIMOL | reporter.nih.gov |
| Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal | NIH | National Cancer Institute | 2021 to 2025 | $3,585,446 | July 1, 2010 | June 30, 2027 | NAKAGAWA, MAYUMI | reporter.nih.gov |
| ED2PrEP - patient focused, low-burden strategies for PrEP uptake among emergency departments patients: a cross-over hybrid implementation-effectiveness trial | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,577,090 | June 24, 2022 | March 21, 2025 | FELSEN, URIEL | reporter.nih.gov |
| Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing (S-ITEST) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $3,529,091 | January 24, 2024 | August 31, 2028 | IWELUNMOR, JULIET | reporter.nih.gov |
| Task A78: Mouse and Guinea Pig Models for Cytomegalovirus and Herpes Simplex Vviruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,527,311 | November 4, 2022 | November 3, 2024 | MADDOX, GRANT | reporter.nih.gov |
| Clinical Study of STI Screening to Prevent Adverse Birth and Newborn Outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,525,168 | January 7, 2020 | December 31, 2025 | KLAUSNER, JEFFREY DAVID | reporter.nih.gov |
| Efficacy of a Trauma Intervention for Affect Regulation, Adherence, and Substance Use to Optimize PrEP for Women Who Inject Drugs | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,503,654 | July 1, 2021 | April 30, 2027 | ROTH, ALEXIS MARIE | reporter.nih.gov |
| Large Scale T Cell Epitope Discovery: Local and Systemic T cell Response to Herpes Simplex Virus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,494,741 | September 30, 2019 | September 29, 2024 | MYER, TIM | reporter.nih.gov |
| Functional genomics for Chlamydia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,489,796 | March 1, 2017 | June 30, 2027 | HYBISKE, KEVIN | reporter.nih.gov |
| Statistical and Data Management Center (SDMC): Microbicide Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $3,470,954 | June 29, 2006 | November 30, 2021 | BROWN, ELIZABETH RENATA | reporter.nih.gov |
| Five Point Initiative: A Cluster Randomized Trial of a Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities | NIH | National Institute of Mental Health | 2023 to 2025 | $3,468,105 | August 5, 2023 | May 31, 2028 | DALE, SANNISHA K | reporter.nih.gov |
| Neisseria gonorrhoeae metal transporters that subvert nutritional immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,458,371 | August 9, 2017 | July 31, 2027 | CORNELISSEN, CYNTHIA N | reporter.nih.gov |
| Testing the impact of a multi-level intervention on cancer prevention behavior among young adults in Texas | NIH | National Cancer Institute | 2021 to 2025 | $3,426,696 | August 1, 2021 | July 31, 2027 | LU, QIAN | reporter.nih.gov |
| Improving HIV Prevention Services among Socioeconomically Disadvantaged Cis-gender Women | NIH | National Institute of Mental Health | 2022 to 2025 | $3,401,345 | August 5, 2022 | May 31, 2027 | COLEMAN, JENELL S | reporter.nih.gov |
| Evaluation of a Treponema pallidum transcription mediated amplification assay for Syphilis Screening | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,378,896 | June 8, 2021 | May 31, 2027 | GOLDEN, MATTHEW R | reporter.nih.gov |
| Virus and olfactory system interactions accelerate Alzheimer's disease pathology | NIH | National Institute on Aging | 2023 to 2025 | $3,375,039 | May 1, 2023 | January 31, 2028 | RESTREPO, DIEGO | reporter.nih.gov |
| Increasing financial and health equity among low income black youth and young adults | NIH | Office of the Director, National Institutes of Health | 2021 | $3,369,104 | September 23, 2021 | August 31, 2023 | LIPPMAN, SHERI ANN | reporter.nih.gov |
| Syphilis Specimen Collection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,361,829 | September 15, 2022 | April 30, 2025 | SENA, ARLENE | reporter.nih.gov |
| Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,356,811 | August 8, 2022 | July 31, 2026 | WANG, LAURENE | reporter.nih.gov |
| Regulated cGAS activation in HSV-1-associated neuropathogenesis. | NIH | National Institute on Aging | 2025 | $3,354,022 | September 15, 2025 | August 31, 2029 | FENG, PINGHUI | reporter.nih.gov |
| Vaginal microbiota transplant to promote Lactobacillus-dominant cervicovaginal communities | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,339,208 | September 20, 2021 | August 31, 2027 | MITCHELL, CAROLINE M | reporter.nih.gov |
| Using parenteral combination adjuvants to induce pan-mucosal cellular and humoral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,332,631 | June 21, 2022 | May 31, 2027 | MCLACHLAN, JAMES B | reporter.nih.gov |
| An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWH | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $3,315,972 | September 24, 2023 | April 30, 2028 | LIU, HONGHU | reporter.nih.gov |
| Enhancing PrEP outcomes among Kenyan adolescent girls and young women with a novel pharmacy-based PrEP delivery platform | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,313,701 | September 22, 2021 | August 31, 2026 | PINTYE, JILLIAN | reporter.nih.gov |
| Epigenetic study of oral HPV infection-associated oral cancer in people living with HIV in Nigeria | NIH | National Cancer Institute | 2022 to 2025 | $3,301,620 | September 16, 2022 | August 31, 2027 | HOU, LIFANG | reporter.nih.gov |
| Impact of HIV, oral microbiome and mycobiome on oral HPV persistence | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $3,289,768 | September 1, 2022 | August 31, 2027 | BURK, ROBERT D | reporter.nih.gov |
| A savings intervention to reduce men's engagement in HIV risk behaviors | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,287,361 | April 1, 2021 | March 30, 2027 | THIRUMURTHY, HARSHA | reporter.nih.gov |
| Clarifying the interplay between herpesvirus infection and reactivation, immune responses, APOE genotype, and development of tau-pathology | NIH | National Institute on Aging | 2025 | $3,280,861 | September 15, 2025 | August 31, 2029 | BJORNEVIK, KJETIL | reporter.nih.gov |
| Conversational Agent to Improve Guideline Concordant Care for People with Cervical Cancer Screening Abnormalities | NIH | National Cancer Institute | 2025 | $3,277,279 | August 15, 2025 | July 31, 2029 | PERKINS, REBECCA BERNSTEIN | reporter.nih.gov |
| Next Generation Multipurpose Intravaginal Ring Technology Using Innovative CLIP 3D Printing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,269,405 | December 1, 2019 | November 30, 2025 | BENHABBOUR, SOUMYA RAHIMA | reporter.nih.gov |
| Structure and function of the portal vertex on the herpes simplex virus capsid | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,250,032 | April 15, 2021 | March 31, 2027 | CONWAY, JAMES F. | reporter.nih.gov |
| Proteasome inhibitors against mucosal protozoan pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,242,175 | September 22, 2021 | August 31, 2026 | ECKMANN, LARS | reporter.nih.gov |
| Keeping it LITE 2: Exploring HIV Risk in Vulnerable Youth with Limited Interaction and Digital Health Intervention (LITE-2) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,236,862 | May 19, 2022 | July 31, 2027 | HOSEK, SYBIL | reporter.nih.gov |
| PRIME: PrEP Intervention for people who Inject MEthamphetamine | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,225,418 | August 1, 2020 | June 30, 2026 | COFFIN, PHILLIP O | reporter.nih.gov |
| Integrated Model for the Prevention of Anal Cancer using screen and Treat for HSIL (IMPACT) | NIH | National Cancer Institute | 2022 to 2025 | $3,210,795 | September 15, 2022 | August 31, 2027 | NOWAK, REBECCA G. | reporter.nih.gov |
| Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,203,991 | July 13, 2020 | July 31, 2027 | KLAUSNER, JEFFREY DAVID | reporter.nih.gov |
| Discovering Our Story, to develop the Chemawa Journey of Transformation | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,201,461 | April 1, 2021 | February 28, 2027 | EVANS-CAMPBELL, TERESA A | reporter.nih.gov |
| Testing a pre-visit mobile health app to promote adolescent healthcare | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $3,197,247 | September 21, 2022 | August 31, 2027 | MARCELL, ARIK V | reporter.nih.gov |
| Development of a Chimeric Syphilis Vaccine Candidate to Combat Local, Disseminated and Congenital Syphilis Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,194,893 | April 15, 2024 | March 31, 2029 | CAMERON, CAROLINE E | reporter.nih.gov |
| Natural History of C. trachomatis urogenital and rectal infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,179,786 | March 20, 2020 | February 28, 2026 | DEAN, DEBORAH ANNE | reporter.nih.gov |
| Leadership and Operations Center (LOC): Microbicide Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $3,164,556 | June 29, 2006 | November 30, 2021 | HILLIER, SHARON L. | reporter.nih.gov |
| Genetics of HSV DNA Replication | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,163,897 | December 1, 1984 | December 31, 2025 | WELLER, SANDRA K | reporter.nih.gov |
| Health Decision-Making in the Aftermath of Disaster | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,159,192 | May 20, 2021 | February 28, 2026 | YANG, DEAN | reporter.nih.gov |
| Intimate Partner Violence and HIV Prevention among Sexual Minority Men | NIH | National Institute of Mental Health | 2021 to 2025 | $3,158,226 | May 1, 2021 | February 28, 2027 | STORHOLM, ERIK D. | reporter.nih.gov |
| Impacting the oral HPV continuum: prevention, screening, and early detection | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $3,152,738 | September 23, 2016 | June 30, 2025 | D'SOUZA, GYPSYAMBER | reporter.nih.gov |
| Coordinated studies in monkeys and humans to assess the immunological impact of rectal Chlamydia trachomatis infection on protection against genital infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,139,154 | April 1, 2023 | March 31, 2028 | VOJTECH, LUCIA N | reporter.nih.gov |
| MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young Men | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $3,138,142 | September 21, 2023 | June 30, 2029 | SCHNALL, REBECCA | reporter.nih.gov |
| Oral microbiome and periodontal diseases in oral HPV infection among people living with HIV | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $3,134,374 | August 11, 2022 | July 31, 2027 | XIAO, CANHUA | reporter.nih.gov |
| ACTION: Study of ACuTe Infections On Novel HIV Prevention Modalities | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,134,333 | July 1, 2022 | June 30, 2027 | KOSS, CATHERINE ANNE STIMETS | reporter.nih.gov |
| Small-Molecule Covalent E6 Antagonists for Treatment of HPV Infection | NIH | National Cancer Institute | 2021 to 2025 | $3,131,524 | May 1, 2021 | April 30, 2027 | ANDROPHY, ELLIOT J. | reporter.nih.gov |
| Reducing cervical cancer screening disparities in Somali immigrant women through a primary care based HPV self-sampling intervention | NIH | National Cancer Institute | 2021 to 2025 | $3,130,772 | June 15, 2021 | May 31, 2027 | PRATT, REBEKAH J. | reporter.nih.gov |
| Cervicovaginal microbiome, mucosal immunity, and pathogen factors that contribute to spontaneous clearance of Chlamydia trachomatis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,127,515 | June 1, 2022 | May 31, 2027 | BROTMAN, REBECCA M. | reporter.nih.gov |
| The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,121,386 | July 18, 2024 | June 30, 2029 | LUETKEMEYER, ANNE FREY | reporter.nih.gov |
| Pay-it-forward gonorrhea testing among men who have sex with men: The PIONEER pragmatic randomized controlled trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,115,633 | March 19, 2021 | February 28, 2027 | TUCKER, JOSEPH DAVID | reporter.nih.gov |
| Resubmission: Multilevel Strategies & Tailored HIV Prevention & Care for Young Couples who use Alcohol & Other Drugs Across Cape Town | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,103,589 | July 1, 2020 | May 31, 2026 | BROWNE, FELICIA AMIRA | reporter.nih.gov |
| EXTENSION OF ESCUDDO FOLLOW-UP FROM FIVE YEARS TO 7.5 YEARS (REFERRED TO AS ESCUDDO-7) | NIH | National Cancer Institute | 2025 | $3,083,060 | March 26, 2025 | September 15, 2025 | reporter.nih.gov | |
| Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,074,527 | May 1, 2021 | April 30, 2027 | MANHART, LISA E | reporter.nih.gov |
| Development of novel anti-Neisseria gonorrhoeae therapeutic agents | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,055,792 | August 12, 2022 | July 31, 2027 | FLAHERTY, DANIEL PATRICK | reporter.nih.gov |
| IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,050,000 | February 1, 2018 | August 31, 2027 | SMITH, THOMAS J. | reporter.nih.gov |
| 3D-bioprinting of sustained- and phased-release antibiotic and probiotic scaffolds to treat bacterial vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,037,595 | February 25, 2022 | January 31, 2028 | FRIEBOES, HERMANN | reporter.nih.gov |
| CHOICES-TEEN: Efficacy of a Bundled Risk Reduction Intervention for Juvenile Justice Females | NIH | National Institute on Drug Abuse | 2021 to 2024 | $3,036,233 | May 15, 2021 | March 31, 2025 | PARRISH, DANIELLE ELIZABETH | reporter.nih.gov |
| Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,015,759 | May 1, 2020 | May 31, 2026 | REITZ, ALLEN BERNARD | reporter.nih.gov |
| Therapy and Prophylaxis for Genital Tract Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,000,000 | February 1, 2013 | July 31, 2026 | AUCI, DOMINICK | reporter.nih.gov |
| VESIVAX TLR7 FORMULA | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $2,999,352 | September 1, 2024 | August 31, 2027 | HO, SAMON | reporter.nih.gov |
| The Empilisweni Initiative - Advancing Implementation of Cervical Cancer Control | NIH | National Cancer Institute | 2023 to 2025 | $2,987,351 | September 19, 2023 | August 31, 2028 | CASTOR, DELIVETTE | reporter.nih.gov |
| Alzheimer's Disease associated pathology induced by neurotropic viral infection | NIH | National Institute on Aging | 2021 to 2025 | $2,972,109 | September 30, 2021 | August 31, 2027 | MURPHY, EAIN A | reporter.nih.gov |
| Parrying the Pitfalls of PrEP: Preventing Premature PrEP Discontinuation and STIs among Young Black MSM | NIH | National Institute of Mental Health | 2021 to 2024 | $2,966,971 | April 16, 2020 | March 31, 2025 | SULLIVAN, PATRICK SEAN | reporter.nih.gov |
| A pragmatic trial of two strategies for implementing an effective eHealth HIV prevention program | NIH | National Institute of Mental Health | 2021 to 2022 | $2,963,835 | August 20, 2018 | May 31, 2025 | MUSTANSKI, BRIAN | reporter.nih.gov |
| Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,960,837 | May 5, 2020 | February 28, 2026 | BAUM, MARC MICHAEL | reporter.nih.gov |
| A low-profile copper intrauterine device that delivers long-acting contraception an | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,953,397 | September 16, 2020 | August 31, 2025 | WOODROW, KIM A. | reporter.nih.gov |
| Observational study to validate circulating HPVDNA and prognostic genomic biomarkers for diagnosis and treatment of HPV-associated OPSCC | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $2,942,933 | July 1, 2020 | April 30, 2026 | YARBROUGH, WENDELL G | reporter.nih.gov |
| Host cell reprogramming by human papillomavirus E7 proteins | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,938,414 | August 1, 2025 | July 31, 2029 | WHITE, ELIZABETH A | reporter.nih.gov |
| An automated, scalable, and rapid AST system for Gonorrhea STIs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,934,394 | January 15, 2021 | December 31, 2023 | SWIGER, ROY R | reporter.nih.gov |
| Identification and analysis of compensatory mutations that support the evolution of antibiotic resistance in Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,923,499 | July 17, 2020 | May 19, 2025 | GRAD, YONATAN H | reporter.nih.gov |
| Improving Adolescent Sexual Health Outcomes using Health Information Technology | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,920,202 | February 1, 2022 | January 31, 2027 | GOYAL, MONIKA KUMARI | reporter.nih.gov |
| Education and employment support for HIV prevention in young adults (ENSPIRE) | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $2,910,835 | July 8, 2021 | March 31, 2027 | JENNINGS MAYO-WILSON, LARISSA | reporter.nih.gov |
| Non-invasive imaging of the anti-tumor immune response | NIH | National Cancer Institute | 2021 to 2025 | $2,904,564 | December 14, 2020 | November 30, 2026 | PISHESHA, NOVALIA | reporter.nih.gov |
| New Engineering Strategy for Harnessing Immune System against Head and Neck Cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,903,162 | July 1, 2021 | April 30, 2026 | MOON, JAMES J. | reporter.nih.gov |
| Development of functional magnetic resonance imaging-guided adaptive radiotherapy for head and neck cancer patients using novel MR-Linac device | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $2,900,314 | August 13, 2019 | May 31, 2025 | FULLER, CLIFTON DAVID | reporter.nih.gov |
| Proteomics-Driven Reverse Vaccinology for Gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,883,482 | February 10, 2022 | January 31, 2027 | SIKORA, ALEKSANDRA ELZBIETA | reporter.nih.gov |
| Neurotropic herpesvirus envelopment and microtubule-mediated transport | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,862,658 | March 15, 2017 | November 30, 2027 | WILSON, DUNCAN W. | reporter.nih.gov |
| Adolescent health behaviors in the time of COVID-19 | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,852,328 | August 20, 2021 | June 30, 2026 | YBARRA, MICHELE L. | reporter.nih.gov |
| Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening | NIH | National Cancer Institute | 2021 to 2025 | $2,851,879 | April 1, 2020 | November 30, 2025 | FANG, CAROLYN Y. | reporter.nih.gov |
| Supporting Informed Parental Decisions on HPV Vaccination through Safe and Personalized AI-Driven Conversations | NIH | National Cancer Institute | 2025 | $2,834,092 | August 15, 2025 | July 31, 2029 | NAN, XIAOLI | reporter.nih.gov |
| Molecular mechanism of cephalosporin resistance of N. gonorrhoeae conferred by mutated PBP2 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,818,329 | March 10, 2022 | February 28, 2027 | DAVIES, CHRISTOPHER | reporter.nih.gov |
| Durable Vaginal Protection from HIV via mRNA expression of BNABS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,806,701 | September 16, 2020 | August 31, 2026 | SANTANGELO, PHILIP J | reporter.nih.gov |
| Mechanism of RB-to-EB Conversion in Chlamydia | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,806,676 | February 1, 2020 | January 31, 2026 | SUETTERLIN, CHRISTINE | reporter.nih.gov |
| Alcohol and "Heat of the Moment" Sexual Decision Making among MSM: Identifying Mechanisms of Sexual Risk and Promoting Behavior Change Through Brief Intervention | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,792,224 | August 15, 2022 | May 31, 2027 | PALFAI, TIBOR P. | reporter.nih.gov |
| Refining Trichomonas vaginalis treatment in women and men. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,787,217 | April 1, 2024 | February 28, 2029 | KISSINGER, PATRICIA J | reporter.nih.gov |
| Determining how a Werner helicase (WRN) tumor suppressor complex regulates the human papillomavirus 16 life cycle | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,779,718 | June 1, 2021 | May 31, 2026 | MORGAN, IAIN | reporter.nih.gov |
| Evaluation of a Combined Motivational Interviewing and Ecological Momentary Intervention to Reduce Risky Alcohol Use among Individuals Vulnerable to HIV/AIDS | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,772,306 | August 15, 2022 | May 31, 2027 | LAUCKNER, CAROLYN | reporter.nih.gov |
| ZAIMARA: Zambian Informed Motivated Aware and Responsible Adolescents and Adults | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $2,766,583 | September 12, 2023 | August 31, 2028 | BOLTON MOORE, CAROLYN | reporter.nih.gov |
| Southwest EDRN Clinical Validation Center for Head and Neck Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,719,420 | August 1, 2023 | July 31, 2028 | ANDERSON, KAREN SUE | reporter.nih.gov |
| The CASCADE CLIMB: Cervical cancer prevention in women Living with HIV research Mobilization Base | NIH | National Cancer Institute | 2022 to 2025 | $2,713,815 | September 20, 2022 | May 31, 2027 | WINER, RACHEL L. | reporter.nih.gov |
| Implementation of evidence-based strategies to optimize HPV vaccination in rural primary care settings | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,685,848 | August 21, 2022 | April 30, 2027 | RODRIGUEZ, ELISA MARIE | reporter.nih.gov |
| Training in Sexually Transmitted Infections and HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,669,926 | July 15, 1990 | June 30, 2027 | SENA-SOBERANO, ARLENE C. | reporter.nih.gov |
| Cervical cancer screening after age 65 in the era of HPV testing: estimating benefits and harms of screening cessation and continuation | NIH | National Cancer Institute | 2022 to 2025 | $2,653,119 | August 1, 2022 | July 31, 2027 | SAWAYA, GEORGE F | reporter.nih.gov |
| Dissecting the role of the Inclusion membrane protein IncE, a master multi-tasking scaffolding protein, in the pathogenesis of Chlamydia trachomatis infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,648,495 | July 22, 2022 | June 30, 2027 | ENGEL, JOANNE N. | reporter.nih.gov |
| Immunity to commensal papillomaviruses for cancer therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,645,679 | May 1, 2021 | April 30, 2027 | DEMEHRI, SHADMEHR | reporter.nih.gov |
| Personalized prevention for couples | NIH | National Institute of Mental Health | 2021 to 2025 | $2,616,164 | July 1, 2021 | June 30, 2027 | MITCHELL, JASON W | reporter.nih.gov |
| The impact of viral genomic variation on neonatal disease outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,609,633 | February 4, 2022 | January 31, 2027 | SZPARA, MORIAH | reporter.nih.gov |
| Mechanisms of Gonococcal Pilin Antigenic and Phase Variation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,608,976 | May 1, 1994 | May 31, 2028 | SEIFERT, HANK S. | reporter.nih.gov |
| Identification of key players mediating internalization of Trichomonas vaginalis extracellular vesicles by host cells and parasite adherence and survival in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,608,762 | June 2, 2020 | May 31, 2026 | JOHNSON, PATRICIA JEAN | reporter.nih.gov |
| Mechanisms Underlying the HIV-HSV-2 Syndemic | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,606,770 | February 20, 2024 | December 31, 2028 | HEROLD, BETSY C. | reporter.nih.gov |
| Chemokine-mediated antigen-specific T cell responses and immunotherapies to treat head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $2,597,804 | July 1, 2020 | April 30, 2026 | PYEON, DOHUN | reporter.nih.gov |
| West Africa Self-Sampling HPV Based Cervical Cancer Control Program (WA-SS-HCCP) for WLWHA: Barriers, challenges, and needs | NIH | National Cancer Institute | 2022 to 2025 | $2,566,495 | September 7, 2022 | August 31, 2027 | HOU, LIFANG | reporter.nih.gov |
| Inborn errors of immunity in children with herpes simplex encephalitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,560,389 | April 6, 2010 | March 31, 2026 | CASANOVA, JEAN-LAURENT | reporter.nih.gov |
| The HPV9-10 Trial: Early Initiation of HPV Vaccination | NIH | National Cancer Institute | 2021 to 2024 | $2,537,601 | May 1, 2020 | April 30, 2026 | KEMPE, ALLISON | reporter.nih.gov |
| PrEP and dPEP: Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,530,733 | August 1, 2019 | July 31, 2025 | BAETEN, JARED | reporter.nih.gov |
| Host Immune Responses to Chlamydia trachomatis Candidate Vaccine Antigens and their Association with Clinical Correlates of Protective Immunity in Women | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,528,516 | May 11, 2020 | April 30, 2026 | GEISLER, WILLIAM M | reporter.nih.gov |
| A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital Herpes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,523,602 | January 10, 2020 | December 31, 2025 | BENMOHAMED, LBACHIR | reporter.nih.gov |
| Human Papillomavirus and Polyomavirus Associated Malignancies. | NIH | National Cancer Institute | 2021 to 2023 | $2,515,952 | September 15, 2017 | August 31, 2024 | GALLOWAY, DENISE A. | reporter.nih.gov |
| TASK A11: MODELS FOR CYTOMEGALOVIRUS AND HERPES SIMPLEX VIRUSES | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,509,649 | September 15, 2025 | September 14, 2026 | BEASLEY, DAVID | reporter.nih.gov |
| Molecular and Cellular Dissection of the Pathogenesis of Herpes Simplex Encephalitis with iPSC-Derived CNS and PNS Cells | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $2,509,626 | September 20, 2010 | March 31, 2025 | CASANOVA, JEAN-LAURENT | reporter.nih.gov |
| TweenVax: A comprehensive practice-, provider-, and parent/patient-level intervention to improve adolescent HPV vaccination. | NIH | National Cancer Institute | 2021 to 2025 | $2,505,141 | July 1, 2024 | June 30, 2027 | BEDNARCZYK, ROBERT A. | reporter.nih.gov |
| Determination of the Interactome between Haemophilus ducreyi and the Human Host. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,502,123 | December 17, 2019 | November 30, 2025 | SPINOLA, STANLEY M. | reporter.nih.gov |
| Social influences on sexual health among Latinx adolescents and emerging adults who identify as LGBTQ+ in an agricultural community | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,500,107 | August 1, 2014 | March 11, 2025 | MINNIS, ALEXANDRA M | reporter.nih.gov |
| STI Response and Recommendations Under PrEP (STIRRUP) | NIH | National Institute of Mental Health | 2022 to 2025 | $2,494,915 | February 1, 2022 | December 31, 2026 | JENNESS, SAMUEL | reporter.nih.gov |
| Microbial Interactions between Gardnerella, Prevotella, and Atopobium Prior to Incident Bacterial Vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,488,193 | February 1, 2020 | January 31, 2026 | MUZNY, CHRISTINA A | reporter.nih.gov |
| Downstream effects of HPV integration on survival/metastasis in oropharyngeal cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,477,895 | July 1, 2020 | December 31, 2025 | SARTOR, MAUREEN AGNES | reporter.nih.gov |
| The CHESS (Community, Home-based Education, Screening Services) Strategy to increase cervical cancer control access for HIV positive women in Nigeria | NIH | National Cancer Institute | 2022 to 2025 | $2,475,158 | September 1, 2022 | August 31, 2027 | FLOWERS, LISA C. | reporter.nih.gov |
| Functional characterization of Chlamydia trachomatis inclusion membrane proteins and their role in subversion of the host vesicular trafficking | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,473,841 | April 1, 2020 | July 31, 2030 | WEBER, MARY | reporter.nih.gov |
| A new molecular therapy against ocular herpes | NIH | National Eye Institute | 2021 to 2025 | $2,467,835 | August 1, 2015 | April 30, 2028 | SHUKLA, DEEPAK | reporter.nih.gov |
| Investigating the role of long-term latent herpes simplex virus infection on APOE4-associated Alzheimer's disease pathogenesis | NIH | National Institute on Aging | 2023 to 2025 | $2,464,653 | August 15, 2023 | April 30, 2028 | NURIEL, TAL | reporter.nih.gov |
| Long-acting multi prevention implant for 2-year contraception and HIV PrEP | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,464,240 | April 1, 2023 | March 31, 2028 | GRATTONI, ALESSANDRO | reporter.nih.gov |
| Integrating a combination HIV prevention intervention into a widely-used geosocial app for Chinese MSM | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,464,184 | January 23, 2019 | December 31, 2024 | SIEGLER, AARON JULIUS | reporter.nih.gov |
| Single arm trial of menstrual cups among economically vulnerable women to reduce Bacterial vaginosis and STIs through reduced harmful sexual and menstrual practices | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,463,754 | August 1, 2025 | July 31, 2027 | MEHTA, SUPRIYA DINESH | reporter.nih.gov |
| Sexual Health and Behavior in a U.S. Probability Sample of Adolescents and Adults | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,460,617 | August 1, 2021 | July 31, 2025 | HERBENICK, DEBRA LYNNE | reporter.nih.gov |
| UNC CASCADE Network Research Base | NIH | National Cancer Institute | 2022 to 2025 | $2,460,562 | September 2, 2022 | May 31, 2027 | SMITH, JENNIFER SUSAN | reporter.nih.gov |
| Genital Immune, Mucosal, and Viral Effects of Female Genital Schistosomiasis in Tanzania | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,453,764 | March 25, 2022 | February 28, 2027 | DOWNS, JENNIFER ALZOS | reporter.nih.gov |
| Task A95: Minimal Inhibitory Concentration (MIC) Testing and Efficacy Studies in a Rabbit Model of Treponema Pallidum Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,453,129 | July 11, 2024 | July 10, 2026 | TZIPORI, SAUL | reporter.nih.gov |
| Targeting the innate immune response in HNSCC | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,451,843 | September 15, 2017 | August 31, 2027 | VARNER, JUDITH A | reporter.nih.gov |
| GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC | NIH | National Institute on Alcohol Abuse and Alcoholism | 2022 to 2025 | $2,441,899 | September 1, 2022 | June 30, 2027 | BROWNE, FELICIA AMIRA | reporter.nih.gov |
| WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,440,496 | January 19, 2024 | November 30, 2028 | GRAHAM, SUSAN MARIE | reporter.nih.gov |
| Screen Smart: Using Digital Health to Improve HIV Screening and Prevention for Adolescents in the Emergency Department | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $2,438,058 | April 13, 2023 | March 31, 2028 | REED, JENNIFER LYNN | reporter.nih.gov |
| A binational cohort of the intersection between substance use, HIV, and associated comorbidities among people who inject drugs in San Diego, CA | NIH | National Institute on Drug Abuse | 2025 | $2,437,310 | July 15, 2025 | May 31, 2030 | STRATHDEE, STEFFANIE A. | reporter.nih.gov |
| Precision imaging for risk stratification and personalized therapy of oropharyngeal cancer | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $2,430,433 | July 5, 2022 | March 31, 2027 | LI, RUIJIANG | reporter.nih.gov |
| Production of a Gonococcal Vaccine for Countering Antimicrobial Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,429,990 | January 1, 2019 | December 31, 2024 | SCHRYVERS, ANTHONY BERNARD | reporter.nih.gov |
| Men's Sexual Risk Behaviors: Alcohol, Sexual Aggression, and Emotional Factors | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2025 | $2,420,010 | June 5, 2018 | August 31, 2028 | DAVIS, KELLY CUE | reporter.nih.gov |
| Toward novel therapies against Lyme disease through the inhibition of lysinoalaine cross-linking in the bacterial flagella. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,405,876 | August 16, 2021 | July 31, 2025 | CRANE, BRIAN R | reporter.nih.gov |
| Primary cilia loss and cell cycle re-entry in Chlamydia-infected cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,401,242 | July 17, 2020 | June 30, 2026 | SUETTERLIN, CHRISTINE | reporter.nih.gov |
| Precision methylation biomarkers for cervical cancer prevention in low resource settings in Latin America | NIH | National Cancer Institute | 2021 to 2023 | $2,399,998 | September 15, 2021 | May 31, 2025 | GUERRERO-PRESTON, RAFAEL | reporter.nih.gov |
| Mechanism of gamma-secretase action during HPV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,393,557 | March 24, 2020 | August 31, 2025 | TSAI, BILLY | reporter.nih.gov |
| Urine based circulating tumor DNA analysis | NIH | National Cancer Institute | 2021 to 2025 | $2,390,011 | July 1, 2021 | June 30, 2026 | LAUTENSCHLAEGER, TIM | reporter.nih.gov |
| Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,388,492 | February 1, 2023 | January 31, 2028 | STRONG, ROLAND K | reporter.nih.gov |
| How sex, host microenvironment, and immune responses shape acquisition of genital bacteria that increase HIV risk | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,387,782 | December 1, 2021 | November 30, 2026 | LIU, CINDY | reporter.nih.gov |
| Roles of sialidase in G. vaginalis-host interactions during bacterial vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,385,117 | December 1, 2014 | November 30, 2025 | LEWIS, AMANDA L. | reporter.nih.gov |
| Comparative Safety of Antibiotics for Common Bacterial Infections During Pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,378,675 | September 2, 2022 | May 31, 2027 | ZHU, YANMIN | reporter.nih.gov |
| Prospective Epidemiologic Study of Novel Etiologic Agents of Pelvic Inflammatory Disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,374,027 | August 1, 2020 | July 31, 2025 | HAGGERTY, CATHERINE L | reporter.nih.gov |
| Understanding and optimizing antibody-based interventions against neonatal HSV infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,367,187 | August 14, 2023 | July 31, 2028 | ACKERMAN, MARGARET E | reporter.nih.gov |
| The Landscape of Tumor intrinsic Genetic Resistance to T cell Therapy | NIH | National Cancer Institute | 2023 to 2025 | $2,350,290 | May 1, 2023 | April 30, 2027 | HINRICHS, CHRISTIAN | reporter.nih.gov |
| A Family-Based HIV Prevention Program for Black Men to Protect Black Girls | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $2,348,430 | September 25, 2023 | May 31, 2028 | CROOKS, NATASHA KAELLA | reporter.nih.gov |
| T-cell activation and exhaustion in the HIV-positive female genital tract | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $2,342,907 | July 5, 2023 | May 31, 2026 | MCCLELLAND, RAYMOND SCOTT | reporter.nih.gov |
| traThe influence of rectal Chlamydia trachomatis infections on immunity and incident urogenital infections in women without an indication forrectal screening | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,340,405 | July 6, 2023 | June 30, 2028 | JORDAN, STEPHEN J. | reporter.nih.gov |
| Anti-Viral therapy in Alzheimer's disease | NIH | National Institute on Aging | 2021 | $2,335,690 | September 15, 2017 | May 31, 2025 | DEVANAND, DAVANGERE P | reporter.nih.gov |
| The natural history of C. trachomatis urethral infections in men who have sex with women | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,335,516 | July 5, 2023 | June 30, 2028 | NELSON, DAVID EMMET | reporter.nih.gov |
| A couples-based HIV biobehavioral prevention intervention | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $2,335,498 | July 15, 2023 | December 31, 2027 | MARTINEZ, OMAR | reporter.nih.gov |
| Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (SCALE) | NIH | National Cancer Institute | 2022 to 2025 | $2,315,714 | April 1, 2022 | March 31, 2027 | CREMER, MIRIAM | reporter.nih.gov |
| AnteroTag, a Novel Method for Trans-Synaptic Delivery of Active Agents to Map and Modify Anterograde Populations | NIH | National Institute of Mental Health | 2021 | $2,304,752 | September 13, 2021 | September 12, 2025 | WILLIAMS, MICHAEL ROLAND | reporter.nih.gov |
| Novel Role for Host Immunostimulatory RNA in Antiviral Immune Defense | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,281,556 | September 22, 2021 | August 31, 2026 | GACK, MICHAELA ULRIKE | reporter.nih.gov |
| Development and Validation of an Artificial-Intelligence-enabled Portable Colposcopy Device for Optimizing Triage Alternatives for HPV-based Cervical Cancer Screening | NIH | National Cancer Institute | 2022 to 2025 | $2,280,935 | May 20, 2022 | April 30, 2027 | RAMANUJAM, NIRMALA | reporter.nih.gov |
| Role of the oral microbiome in driving local and systemic inflammation in HIV | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $2,277,570 | August 1, 2023 | July 31, 2028 | FULCHER, JENNIFER | reporter.nih.gov |
| Bridges-Round 2: Evaluating the Long-term Impact of a Family Economic Empowerment Intervention on HIV Risk Prevention and Care Continuum Outcomes among Orphaned Youth Transitioning to Young Adulthood | NIH | National Institute of Mental Health | 2022 to 2025 | $2,274,945 | March 17, 2022 | February 28, 2027 | SSEWAMALA, FRED M | reporter.nih.gov |
| Single-cell multi-region dissection of AD-pathogen interactions for HSV-1 and CMV | NIH | National Institute on Aging | 2023 to 2025 | $2,266,769 | February 1, 2023 | January 31, 2028 | KELLIS, MANOLIS | reporter.nih.gov |
| The Microbiome and Mucosal Immunity in Cervical Cancer Disparities | NIH | National Cancer Institute | 2022 to 2025 | $2,247,793 | April 25, 2022 | March 31, 2027 | BURGENER, ADAM | reporter.nih.gov |
| Investigations Into The Molecular Pathogenesis Of Cervical Glandular Neoplasias | NIH | National Cancer Institute | 2021 to 2024 | $2,242,414 | July 2, 2020 | June 30, 2025 | BURK, ROBERT D | reporter.nih.gov |
| A pH Responsive Transistor-like Nanoprobe for Sensitive Detection of Unknown Primary Cancers of the Head and Neck | NIH | National Cancer Institute | 2022 to 2025 | $2,234,520 | June 1, 2022 | May 31, 2027 | SUMER, BARAN D | reporter.nih.gov |
| Improved Nanoparticle Targeting of Tissue Myeloid Cells for HIV-1 Long-acting Pre-exposure Prophylaxis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,233,984 | March 17, 2023 | February 28, 2027 | REINHARD, BJOERN MARKUS | reporter.nih.gov |
| Mechanism of Herpes Simplex Virus (HSV) Induced Membrane Fusion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,232,423 | December 1, 2019 | November 30, 2025 | LONGNECKER, RICHARD M | reporter.nih.gov |
| Human papillomavirus entry: late trafficking and establishment of infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,224,965 | July 1, 2021 | June 30, 2027 | ZWOLINSKA, KATARZYNA | reporter.nih.gov |
| Evaluating the effectiveness of a mobile HIV prevention app to increase HIV and STI testing and PrEP initiation | NIH | National Institute of Mental Health | 2023 to 2025 | $2,221,938 | August 1, 2023 | April 30, 2028 | JONES, JEB | reporter.nih.gov |
| Viral and Host Factors in Herpetic Diseases | NIH | National Eye Institute | 2021 to 2025 | $2,206,794 | January 9, 1992 | June 30, 2027 | LEIB, DAVID A | reporter.nih.gov |
| Improving HIV testing, linkage, and retention in care for men through U=U messaging | NIH | National Institute of Mental Health | 2022 to 2025 | $2,205,152 | June 1, 2022 | April 30, 2027 | MEDINA-MARINO, ANDREW | reporter.nih.gov |
| Targeting the functions of the gonococcal Type IV pilus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,204,820 | August 1, 2020 | August 31, 2030 | SEIFERT, HANK S. | reporter.nih.gov |
| Minor Consent Laws and HIV Prevention Among Adolescents in the United States | NIH | National Institute of Mental Health | 2021 to 2024 | $2,187,850 | December 25, 2019 | October 31, 2025 | NELSON, KIMBERLY M | reporter.nih.gov |
| Spindle Orientation in Skin Development and Homeostasis | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,187,442 | September 1, 2015 | August 31, 2026 | LECHLER, TERRY H | reporter.nih.gov |
| A novel vaccine against multidrug-resistant gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,179,764 | January 1, 2019 | December 31, 2024 | RAM, SANJAY | reporter.nih.gov |
| The flavin-centric metabolic lifestyle of Treponema pallidum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,174,492 | July 1, 2003 | November 30, 2024 | HENDRIXSON, DAVID R | reporter.nih.gov |
| Ordered gene knockout libraries for Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,169,654 | July 1, 2021 | June 30, 2025 | SEIFERT, HANK S. | reporter.nih.gov |
| Group testing for infectious disease detection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,164,953 | May 24, 2016 | June 30, 2027 | BILDER, CHRISTOPHER R | reporter.nih.gov |
| Oral HPV Research Among Latin Americans Living with HIV (ORAL - H² Study) | NIH | National Cancer Institute | 2022 to 2025 | $2,160,881 | September 12, 2022 | August 31, 2028 | GIULIANO, ANNA R. | reporter.nih.gov |
| Impact of the vaginal microbiome on Chlamydia trachomatis acquisition | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,158,356 | January 14, 2019 | December 31, 2025 | MCCLELLAND, RAYMOND SCOTT | reporter.nih.gov |
| Low-cost mobile colposcopy and confocal imaging for global prevention of cervical cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,157,600 | August 1, 2020 | April 30, 2026 | RICHARDS-KORTUM, REBECCA R. | reporter.nih.gov |
| Impacts of structural and system-level interventions on HIV/STI and overdose epidemics among SWs | NIH | National Institute on Drug Abuse | 2021 to 2024 | $2,156,134 | July 15, 2010 | March 31, 2026 | KRUSI, ANDREA | reporter.nih.gov |
| Assessing the use of MY-RIDE, a just-in-time adaptive intervention, to Improve HIV prevention and Substance Use in Youth Experiencing Homelessness | NIH | National Institute of Nursing Research | 2023 to 2025 | $2,155,834 | September 21, 2023 | June 30, 2027 | SANTA MARIA, DIANE M. | reporter.nih.gov |
| Understanding the Role of HAART in the Progression of HPV-Associated Oral Cancer | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2025 | $2,153,755 | July 11, 2022 | May 31, 2027 | MEYERS, CRAIG M | reporter.nih.gov |
| Optimizing PrEP adherence in sexual minority men who use stimulants | NIH | National Institute on Drug Abuse | 2021 to 2022 | $2,152,006 | July 1, 2020 | July 3, 2023 | CARRICO, ADAM WAYNE | reporter.nih.gov |
| Biomarker Approach to Screening for the early detection of HPV-related Oropharyngeal Cancer (BASH OPC) | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $2,145,712 | September 4, 2023 | June 30, 2028 | GIULIANO, ANNA R. | reporter.nih.gov |
| Multilevel Comprehensive HIV Prevention for South African Adolescent Girls and Young Women | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,127,826 | September 1, 2018 | December 31, 2024 | DONENBERG, GERI R | reporter.nih.gov |
| Modeling of human HSV infection: development of immune-competent 3D skin-on-chip with vascular perfusion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,127,442 | February 15, 2020 | January 31, 2026 | ZHU, JIA | reporter.nih.gov |
| A Randomized Clinical Trial to Assess the Effectiveness of Ablative Treatments for Cervical Cancer Risk Reduction in HIV+ Women living in Mozambique | NIH | National Cancer Institute | 2022 to 2025 | $2,124,467 | May 12, 2020 | July 31, 2027 | SCHMELER, KATHLEEN | reporter.nih.gov |
| Papillomavirus E6 cellular targets | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,121,550 | September 17, 2021 | August 31, 2025 | VANDE POL, SCOTT BRIAN | reporter.nih.gov |
| Couples Motivational Interviewing to reduce drug use and HIV risk in vulnerable male couples | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,117,921 | September 30, 2023 | July 31, 2028 | STARKS, TYREL J | reporter.nih.gov |
| Low-Cost CRISPR-on-Paper for Cervical Cancer Screening at the Point of Care | NIH | National Cancer Institute | 2022 to 2025 | $2,114,061 | May 1, 2022 | April 30, 2026 | LIU, CHANGCHUN | reporter.nih.gov |
| Impact of Menstruation on Chlamydial and Gonorrhea Infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,112,000 | September 22, 2025 | August 31, 2029 | KOHLMEIER, ALISON SWAIMS | reporter.nih.gov |
| Real-world effectiveness of HPV vaccine in women living with HIV and its impact on cervical cancer screening accuracies | NIH | National Cancer Institute | 2023 to 2025 | $2,109,984 | May 1, 2023 | April 30, 2029 | MOSCICKI, ANNA-BARBARA | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,107,829 | September 1, 2020 | February 28, 2025 | RICE, PETER | reporter.nih.gov |
| HPV16 E6 Antibody Detection as an Early Marker for Oropharyngeal Cancer Among Men Living with HIV | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $2,105,308 | February 5, 2021 | April 30, 2026 | KUHS, KRYSTLE A. | reporter.nih.gov |
| Screening Strategies Among High-Risk Populations for Anal Cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,102,573 | September 12, 2023 | August 31, 2029 | FLOWERS, LISA C. | reporter.nih.gov |
| Cargo, biogenesis and functions of extracellular vesicles released during HSV-1 infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,080,310 | July 1, 2021 | June 30, 2027 | KALAMVOKI, MARIA | reporter.nih.gov |
| PCOM2 - The Physician Communication Intervention, Version 2.0 | NIH | National Cancer Institute | 2022 to 2025 | $2,078,331 | January 15, 2022 | December 31, 2026 | O'LEARY, SEAN T | reporter.nih.gov |
| Therapeutic control of HSK by CD80 | NIH | National Eye Institute | 2021 to 2025 | $2,074,975 | September 1, 2016 | November 30, 2026 | GHIASI, HOMAYON | reporter.nih.gov |
| Large-Scale T Cell Immune Epitope Discovery and Mechanisms of T Cell Protection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,069,401 | September 30, 2025 | September 29, 2026 | KOELLE, DAVID | reporter.nih.gov |
| Understanding pathogen and host determinants of the natural history of N. gonorrhoeae infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,068,068 | June 23, 2023 | May 31, 2028 | DUNCAN, JOSEPH A | reporter.nih.gov |
| Syphilis in Pregnancy Study (SIPS): Molecular Diagnostics and Maternal and Infant Immune Response to Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,045,766 | June 23, 2023 | May 31, 2028 | DIONNE, JODIE ANN | reporter.nih.gov |
| HPSE in Ocular Herpes Infection | NIH | National Eye Institute | 2021 to 2025 | $2,043,774 | September 1, 2018 | August 31, 2027 | SHUKLA, DEEPAK | reporter.nih.gov |
| Understanding the rectal mucosal effects of cross-sex hormone therapy among US and Thai transgender women | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,037,903 | August 1, 2019 | July 31, 2025 | KELLEY, COLLEEN F | reporter.nih.gov |
| Modernizing Perinatal Syphilis Testing | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2023 to 2025 | $2,034,575 | December 21, 2022 | November 30, 2027 | STAFFORD, IRENE A. | reporter.nih.gov |
| HSV/VZV chimeric viruses for identifying critical virus herpesvirus assembly interactions | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,023,505 | February 1, 2022 | January 31, 2027 | ROLLER, RICHARD J | reporter.nih.gov |
| Intimate Partner Violence and HIV Prevention Continuum Engagement Among Populations Most Affected by HIV in the United States | NIH | National Institute of Mental Health | 2023 to 2025 | $2,022,700 | September 15, 2023 | June 30, 2028 | STORHOLM, ERIK D. | reporter.nih.gov |
| Automated Digital Imaging for Cervical Cancer Screening | NIH | National Cancer Institute | 2021 to 2024 | $2,017,495 | July 6, 2020 | March 12, 2025 | KUHN, LOUISE | reporter.nih.gov |
| Molecular Biology of Oncogenic Papillomaviruses | NIH | National Cancer Institute | 2021 to 2022 | $2,013,620 | January 1, 2016 | December 31, 2023 | HOWLEY, PETER M | reporter.nih.gov |
| Gonococci: Genetics of Resistance to PMN Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,011,486 | April 1, 1984 | August 31, 2026 | SHAFER, WILLIAM MAURICE | reporter.nih.gov |
| Characterizing Mucosal Changes in the FRT Leading to Increased HIV Acquisition | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,011,011 | April 1, 2019 | March 31, 2025 | HOPE, THOMAS | reporter.nih.gov |
| Phase 2 placebo-controlled randomized trial of LACTIN-V (Lactobacillus crispatus CTV-05) among women at high risk of HIV acquisition in Durban, South Africa | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $2,007,226 | June 12, 2019 | March 31, 2025 | COHEN, CRAIG R | reporter.nih.gov |
| Estimating the cost of peer specialists providing comprehensive healthcare services at a syringe services program | NIH | National Institute on Drug Abuse | 2023 to 2025 | $2,007,015 | June 1, 2023 | March 31, 2028 | TOOKES, HANSEL EMORY | reporter.nih.gov |
| Syphilis Immunology and Biology to Improve Clinical Management and Vaccine Design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,005,343 | November 1, 2024 | October 31, 2028 | KLAUSNER, JEFFREY DAVID | reporter.nih.gov |
| Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care | NIH | National Cancer Institute | 2022 to 2024 | $2,002,128 | September 1, 2022 | April 1, 2025 | PAASCHE-ORLOW, MICHAEL | reporter.nih.gov |
| Experimental Gonococcal Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | January 1, 2015 | June 30, 2023 | AUCI, DOMINICK | reporter.nih.gov |
| Integrated Health Services (IHS) Project | NIH | Office of the Director, National Institutes of Health | 2023 to 2025 | $2,000,000 | September 22, 2023 | September 21, 2028 | GIPSON, JUNE ARNESSA | reporter.nih.gov |
| Synthetic mRNA-mediated reversible immunocontraception | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,998,401 | September 13, 2019 | August 31, 2025 | SANTANGELO, PHILIP J | reporter.nih.gov |
| PROGRESS: PRevention of cervical cancer using the Genotyping scREening and Same-day Self-sampling | NIH | National Cancer Institute | 2022 to 2023 | $1,997,669 | September 5, 2022 | August 31, 2025 | WANG, YOUXIANG | reporter.nih.gov |
| Validation of a lab-free low-cost screening test for prevention of cervical cancer: automated visual evaluation | NIH | National Cancer Institute | 2023 to 2025 | $1,996,573 | July 1, 2020 | August 31, 2026 | LEVITZ, DAVID | reporter.nih.gov |
| Innovations in cervical cancer diagnosis for low resource settings using advanced optical imaging and machine learning diagnostic algorithms. | NIH | National Cancer Institute | 2022 to 2023 | $1,994,001 | September 13, 2019 | June 30, 2025 | KRIEGER, MARLEE | reporter.nih.gov |
| Point of Care HPV 16/18/45 DNA Test for Cervical Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,988,443 | September 22, 2023 | February 28, 2026 | CHO, HYUNDAE | reporter.nih.gov |
| Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,982,258 | March 1, 2017 | July 31, 2025 | TRABBIC, KEVIN | reporter.nih.gov |
| Therapeutic Targeting of Macrophage PI3Kgamma in HNSCC | NIH | National Cancer Institute | 2021 to 2025 | $1,980,814 | April 17, 2018 | November 30, 2028 | VARNER, JUDITH A | reporter.nih.gov |
| Viral determinants in HSV virulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,980,045 | May 15, 2020 | July 31, 2025 | HE, BIN | reporter.nih.gov |
| Low-Cost Instrument-free Point-of-Care Test for Chlamydia and Gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,974,336 | April 22, 2020 | March 31, 2024 | SINGH, SHEENA DEVIKA | reporter.nih.gov |
| The role of secreted effector proteins in Chlamydia trachomatis invasion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,960,408 | September 22, 2020 | August 31, 2025 | WEBER, MARY | reporter.nih.gov |
| Factors Affecting longterm in vitro culture of Treponema pallidum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,959,695 | September 17, 2018 | April 30, 2029 | EDMONDSON, DIANE G | reporter.nih.gov |
| National Implementation of an evidence-based HIV prevention program: multilevel scale-up strategies and precision prevention | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $1,953,669 | August 15, 2018 | August 31, 2030 | WANG, BO | reporter.nih.gov |
| Biomedical HIV prevention messaging among adolescents | NIH | National Institute of Mental Health | 2023 to 2025 | $1,941,948 | May 16, 2023 | February 29, 2028 | MACAPAGAL, KATHRYN ROSE | reporter.nih.gov |
| Elucidation of genetic networks of HSV-1 virion proteins and discovery of their functions in the morphogenesis of the infectious virus particle | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,940,121 | January 10, 2019 | December 31, 2025 | DESAI, PRASHANT J | reporter.nih.gov |
| Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | NIH | National Institute on Drug Abuse | 2021 to 2024 | $1,939,313 | April 15, 2019 | January 31, 2026 | GRYCZYNSKI, JAN | reporter.nih.gov |
| Virus-host interactions governing alpha-herpesvirus genome delivery and neuroinvasion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,932,689 | February 1, 2020 | January 31, 2026 | SMITH, GREGORY ALLAN | reporter.nih.gov |
| Targeting replication stress and homologous recombination repair mechanisms in HPV-positive and negative head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2025 | $1,921,017 | July 1, 2021 | April 30, 2027 | OSMAN, ABDULLAH ALI | reporter.nih.gov |
| Host-pathogen interactions controlling Chlamydia developmental cycle | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,918,884 | August 1, 2021 | July 31, 2027 | DERRE, ISABELLE | reporter.nih.gov |
| PI3K Pathway Mutations in Head and Neck Cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $1,916,929 | May 1, 2014 | May 31, 2026 | GRANDIS, JENNIFER RUBIN | reporter.nih.gov |
| Human papillomavirus in HIV associated lung cancers | NIH | National Cancer Institute | 2021 to 2025 | $1,915,370 | April 1, 2021 | March 31, 2027 | LIN, ZHEN | reporter.nih.gov |
| Therapy and Prophylaxis for Genital Tract Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,915,331 | February 1, 2013 | April 30, 2023 | AUCI, DOMINICK | reporter.nih.gov |
| Advancing the implementation of evidence-based strategies for HPV vaccination in safety-net primary care settings | NIH | National Cancer Institute | 2021 to 2025 | $1,912,883 | August 20, 2020 | April 30, 2027 | TSUI, JENNIFER | reporter.nih.gov |
| HPV, HIV and Oral Microbiota Interplay in Nigerian Youth (HOMINY) | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,910,616 | August 1, 2024 | July 31, 2027 | COKER, MODUPE | reporter.nih.gov |
| From Academia to Business: Development of Novel Therapeutics Against HPV-Associated Cancer | NIH | National Cancer Institute | 2023 to 2024 | $1,909,685 | May 1, 2023 | April 30, 2026 | RIETZ, ANNE | reporter.nih.gov |
| PREVENT - Practice-based Approaches to Promote HPV Vaccination | NIH | National Cancer Institute | 2023 to 2025 | $1,908,049 | May 15, 2023 | April 30, 2028 | KEPKA, DEANNA LEE | reporter.nih.gov |
| An inoculation theory-based messaging intervention addressing misinformation about HPV vaccine on social media: The Inoculate for HPV Vaccine randomized controlled trial | NIH | National Cancer Institute | 2022 to 2025 | $1,903,422 | April 12, 2022 | April 2, 2025 | KORNIDES, MELANIE LYNN | reporter.nih.gov |
| Analysis of high dimensional genomic dataset to reveal mechanistic insights on divergent outcomes of head and neck cancer using system biology modeling coupled with experimental validation | NIH | National Institute of Dental & Craniofacial Research | 2025 | $1,899,042 | September 19, 2025 | September 18, 2028 | WANG, JING HONG | reporter.nih.gov |
| Intrarectal Immunization for a Barrier to Mucosal HIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,888,173 | April 19, 2024 | February 28, 2029 | GAUDUIN, MARIE-CLAIRE ELISABETH | reporter.nih.gov |
| Harnessing the power of technology to develop a population-based HIV prevention program for trans girls | NIH | National Institute of Nursing Research | 2021 to 2024 | $1,872,429 | September 8, 2021 | June 30, 2025 | YBARRA, MICHELE L. | reporter.nih.gov |
| Effects of HSV-1 infection on neural progenitor cell biology in vitro and in vivo | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,871,397 | July 1, 2020 | April 30, 2026 | D'AIUTO, LEONARDO | reporter.nih.gov |
| Acceptability and feasibility of combination treatment for cervical precancer among South Africa women living with HIV | NIH | National Cancer Institute | 2021 to 2024 | $1,863,953 | June 1, 2020 | May 31, 2026 | CHIBWESHA, CARLA J | reporter.nih.gov |
| Optimizing PrEP adherence in sexual minority men who use stimulants | NIH | National Institute on Drug Abuse | 2023 to 2024 | $1,855,864 | July 1, 2020 | May 31, 2025 | CARRICO, ADAM WAYNE | reporter.nih.gov |
| The Clinical History of Rectal and Urethral STIs among MSM: characterizing microbiome host immune interactions for diagnostic and vaccine advances | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,855,034 | August 1, 2025 | July 31, 2028 | MEHTA, SUPRIYA DINESH | reporter.nih.gov |
| Effectiveness of PrEP product choice on HIV prevention coverage among young women in Kenya seeking reproductive health services | NIH | National Institute of Mental Health | 2023 to 2025 | $1,854,463 | September 14, 2023 | July 31, 2028 | HEFFRON, RENEE A. | reporter.nih.gov |
| Neoadjuvant immunoradiotherapy for HPV mediated oropharynx cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,854,023 | September 18, 2023 | July 31, 2028 | CALIFANO, JOSEPH A | reporter.nih.gov |
| Meet me where I am: A multilevel strategy to increase PrEP uptake and persistence among young sexual and gender minority men in rural NC | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,854,022 | June 13, 2022 | May 31, 2026 | RUTSTEIN, SARAH E. | reporter.nih.gov |
| The STOP-HPV Scale-Up Study | NIH | National Cancer Institute | 2023 to 2025 | $1,836,530 | April 1, 2023 | March 31, 2028 | SZILAGYI, PETER G | reporter.nih.gov |
| The role of the microbiome in HPV-associated cervical cancer in women with HIV | NIH | National Cancer Institute | 2021 to 2024 | $1,836,170 | May 6, 2020 | April 30, 2026 | UHLEMANN, ANNE-CATRIN | reporter.nih.gov |
| Cellular mechanisms by which Neisseria gonorrhoeae infects the female reproductive tract | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,833,955 | July 5, 2019 | April 30, 2030 | SONG, WENXIA | reporter.nih.gov |
| Optimizing the Generation of Monoclonal Antibodies for Prevention and Treatment of HSV Disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,825,832 | June 6, 2023 | May 31, 2028 | HEROLD, BETSY C. | reporter.nih.gov |
| Impact of Aging on Mucosal Immune Protection in the Female Reproductive | NIH | National Institute on Aging | 2021 to 2023 | $1,824,844 | March 1, 2019 | December 31, 2024 | WIRA, CHARLES ROBERT | reporter.nih.gov |
| The Hippo Signaling Pathway in High Grade Serous Ovarian Carcinoma | NIH | National Cancer Institute | 2021 to 2025 | $1,811,794 | May 1, 2016 | August 31, 2026 | WANG, CHENG | reporter.nih.gov |
| Efficacy trial for a smartphone game to prevent HIV among young Africans | NIH | National Institute of Mental Health | 2021 to 2023 | $1,811,052 | September 12, 2019 | July 31, 2025 | WINSKELL, S KATE | reporter.nih.gov |
| Increased risk of STI and HIV among adolescent girls and young women due to COVID-19 and pandemic mitigation: Biological, behavioral, and psychosocial mediators | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $1,810,346 | September 19, 2021 | June 30, 2025 | MEHTA, SUPRIYA DINESH | reporter.nih.gov |
| Regulatory Role of Tandem Tryptophan Codons in Chlamydial Persistence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,807,001 | February 8, 2019 | January 31, 2025 | CARABEO, REY A | reporter.nih.gov |
| Come As You Are - Assessing the Efficacy of a Nurse Case Management HIV Prevention and Care Intervention among Homeless Youth | NIH | National Institute of Nursing Research | 2021 to 2023 | $1,806,821 | January 9, 2019 | May 31, 2024 | SANTA MARIA, DIANE M. | reporter.nih.gov |
| Genomics approaches to elucidating pathways to antibiotic resistance in Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,805,779 | July 1, 2017 | May 31, 2028 | GRAD, YONATAN H | reporter.nih.gov |
| Harnessing the power of peer navigation and mHealth to reduce health disparities in Appalachia | NIH | National Institute of Nursing Research | 2021 to 2024 | $1,805,022 | August 27, 2020 | March 21, 2025 | RHODES, SCOTT D | reporter.nih.gov |
| Assessing the effects of a multisectoral agricultural intervention on the reproductive and sexual health of adolescent girls and young women | NIH | National Institute of Mental Health | 2024 to 2025 | $1,803,333 | August 1, 2024 | May 31, 2029 | WEISER, SHERI DAWN | reporter.nih.gov |
| The effectiveness, cost-effectiveness, and budget impact of interventions to improve the delivery of cervical cancer screening in Puerto Rico. | NIH | National Cancer Institute | 2023 to 2025 | $1,791,615 | September 19, 2023 | August 31, 2028 | ORTIZ, ANA PATRICIA | reporter.nih.gov |
| Antiviral and immunomodulatory effects of interferon lambda in the skin | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,784,166 | March 13, 2023 | February 29, 2028 | LAZEAR, HELEN | reporter.nih.gov |
| Expedited Partner Therapy and the HIV Prevention Cascade Among MSM in Peru | NIH | National Institute of Mental Health | 2021 to 2023 | $1,783,094 | June 1, 2019 | March 31, 2025 | CLARK, JESSE LAWTON | reporter.nih.gov |
| Emerging Infectious Disease and HIV Scholars Program at Brown University | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,768,801 | August 1, 2018 | July 31, 2028 | CHIANG, SILVIA SHINPEI | reporter.nih.gov |
| Mouse modeling of HPV infection | NIH | National Cancer Institute | 2021 to 2023 | $1,759,688 | December 1, 2018 | November 30, 2024 | HUNG, CHIEN-FU | reporter.nih.gov |
| Targeting non-canonical p16 signaling to improve radiation response and outcome in head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $1,754,171 | June 15, 2023 | May 31, 2028 | SKINNER, HEATH DEVIN | reporter.nih.gov |
| Virus-cell interactions affecting HSV gene expression | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,748,488 | March 1, 1992 | October 31, 2026 | DELUCA, NEAL A. | reporter.nih.gov |
| Cross talk between keratinocytes and skin-resident T-cells influences HSV recurrence | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,744,756 | July 12, 2024 | June 30, 2029 | ZHU, JIA | reporter.nih.gov |
| Mechanisms and Correlates of Immune Protection against Genital Chlamydia in Humans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,741,985 | December 1, 2011 | June 30, 2025 | GEISLER, WILLIAM M | reporter.nih.gov |
| Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,732,492 | June 1, 2024 | May 31, 2027 | GUERRERO-PRESTON, RAFAEL | reporter.nih.gov |
| A novel, one stop, affordable, point of care and artificial intelligence supported system of screening, triage and treatment selection for cervical cancer and precancer in the LMICs | NIH | National Cancer Institute | 2023 to 2025 | $1,730,892 | August 15, 2023 | July 31, 2028 | BASU, PARTHA | reporter.nih.gov |
| Role of local antibodies in control of chronic genital herpes | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,727,127 | February 5, 2024 | December 31, 2028 | SHOLUKH, ANTON M | reporter.nih.gov |
| Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy | NIH | National Cancer Institute | 2021 to 2023 | $1,725,233 | April 1, 2019 | March 31, 2024 | WU, TZYY-CHOOU | reporter.nih.gov |
| Mapping Protein Interaction Networks Essential for Gonococcal Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,721,728 | May 6, 2021 | April 30, 2026 | EMILI, ANDREW | reporter.nih.gov |
| A Randomized Controlled Trial of Mail-Self Stamped HPV Testing to Increase Cervical Cancer Screening Participation Among Minority/Underserved Women in an Integrated Safety Net Healthcare System | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $1,713,104 | April 16, 2019 | March 19, 2023 | MONTEALEGRE, JANE R | reporter.nih.gov |
| Self-Testing Options in the era of Primary HPV screening for cervical cancer: the STEP trial | NIH | National Cancer Institute | 2021 to 2023 | $1,711,156 | July 1, 2019 | December 31, 2024 | GREEN, BEVERLY BETH | reporter.nih.gov |
| Technology-based Training Tool for an Empirically-Supported Group-Based HIV and STI Prevention Intervention for Juvenile Offenders | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2023 | $1,703,673 | September 18, 2019 | November 30, 2024 | SMITH, DAVID RANDOLPH | reporter.nih.gov |
| Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,702,035 | April 1, 2021 | March 31, 2024 | KUSHIRO, KEIICHIRO | reporter.nih.gov |
| Enlisting HPV integration events to illuminate drivers and target treatment in invasive cervical cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,681,974 | July 15, 2022 | June 30, 2027 | RADER, JANET S. | reporter.nih.gov |
| Genetic analysis of mechanisms of chlamydial immune evasion | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,680,687 | February 1, 2012 | March 31, 2025 | NELSON, DAVID EMMET | reporter.nih.gov |
| Novel vaccine antigens against N. gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,680,515 | September 8, 2022 | August 31, 2027 | MASSARI, PAOLA | reporter.nih.gov |
| Chlamydia type III effectors affecting the host actin-based cytoskeleton | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,678,770 | February 6, 2023 | January 31, 2028 | FIELDS, KENNETH A | reporter.nih.gov |
| High-risk HPV E6: dysregulation of immortalization, growth, and differentiation through protein partnerships in HPV-associated cancers | NIH | National Cancer Institute | 2021 to 2024 | $1,677,482 | June 4, 2014 | May 31, 2026 | KATZENELLENBOGEN, RACHEL ADRIA | reporter.nih.gov |
| HPV, HIV and Oral Microbiota Interplay in Nigerian Youth (HOMINY) | NIH | National Institute of Dental & Craniofacial Research | 2022 to 2023 | $1,672,805 | August 1, 2022 | July 31, 2024 | COKER, MODUPE | reporter.nih.gov |
| A Novel, Multi-compartment Intravaginal Ring for Prevention of Genital Herpes and Unintended Pregnancy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,670,110 | September 10, 2024 | July 31, 2029 | BAUM, MARC MICHAEL | reporter.nih.gov |
| Violence and onward HIV transmission in perinatally-infected adolescents | NIH | National Institute of Mental Health | 2021 to 2023 | $1,667,236 | August 15, 2019 | May 31, 2025 | KIDMAN, RACHEL | reporter.nih.gov |
| Enhancing surveillance systems to slow the spread of antimicrobial-resistant gonorrhea in the United States | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,666,940 | June 23, 2020 | May 31, 2026 | YAESOUBI, REZA | reporter.nih.gov |
| Ocular HSV: Mechanism of virus reactivation | NIH | National Eye Institute | 2021 to 2025 | $1,664,750 | May 1, 2018 | December 31, 2027 | GHIASI, HOMAYON | reporter.nih.gov |
| An R2 non-neuroinvasive herpes simplex virus type 2 vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,664,299 | June 1, 2024 | May 31, 2027 | SMITH, GREGORY ALLAN | reporter.nih.gov |
| Immunogenomic predictors of outcomes in patients with locally advanced cervical cancer treated with immunotherapy and chemoradiation | NIH | National Cancer Institute | 2023 to 2025 | $1,661,015 | July 1, 2023 | June 30, 2026 | ZAMARIN, DMITRIY | reporter.nih.gov |
| Transcriptomics-based identification of cell type specific host genes and gene networks perturbed by HSV-1 in cerebral organoids. | NIH | National Institute on Aging | 2024 to 2025 | $1,658,235 | July 15, 2024 | April 30, 2029 | LIM, TENG-TING ELAINE | reporter.nih.gov |
| Examining the effect of cadmium metal exposure on Alzheimer's disease genetic alleles using herpes viral infected cerebral organoids | NIH | National Institute on Aging | 2024 to 2025 | $1,658,220 | September 15, 2024 | June 30, 2029 | CHAN, YING LEONG | reporter.nih.gov |
| The Role of gK in HSV-1 Induced Corneal Scarring | NIH | National Eye Institute | 2021 to 2024 | $1,657,475 | September 9, 2002 | March 31, 2026 | GHIASI, HOMAYON | reporter.nih.gov |
| Effectiveness of the HPV Vaccine in Immunocompromised Populations | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,654,519 | July 9, 2024 | May 31, 2029 | SILVERBERG, MICHAEL J | reporter.nih.gov |
| Rapid Point of Care Detection of HPV-Associated Malignancies | NIH | National Cancer Institute | 2021 to 2022 | $1,645,226 | May 12, 2017 | August 31, 2024 | ANDERSON, KAREN SUE | reporter.nih.gov |
| Contribution of sympathetic nerves to herpes stromal keratitis | NIH | National Eye Institute | 2022 to 2025 | $1,640,004 | April 1, 2017 | March 31, 2027 | ST LEGER, ANTHONY J | reporter.nih.gov |
| HSV-1 Encoded MicroRNAs in the Pathogenesis and Treatment of Ocular Herpes | NIH | National Eye Institute | 2022 to 2025 | $1,640,000 | March 1, 2022 | December 31, 2026 | SHUKLA, DEEPAK | reporter.nih.gov |
| Developing A Tissue-Targeted Ocular HSV Therapeutic Vaccine | NIH | National Eye Institute | 2022 to 2025 | $1,639,996 | September 1, 2010 | March 31, 2027 | BENMOHAMED, LBACHIR | reporter.nih.gov |
| Evaluation of the Teal self-collect device for cervical cancer screening | NIH | National Cancer Institute | 2024 to 2025 | $1,628,469 | September 23, 2024 | August 31, 2026 | DEPEL, TRENA | reporter.nih.gov |
| Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach | NIH | National Cancer Institute | 2023 to 2025 | $1,622,893 | July 1, 2023 | June 30, 2028 | CASTRO, CESAR M | reporter.nih.gov |
| Functional Analysis of the Clp Protease Systems in Chlamydial Growth and Differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,617,673 | July 1, 2022 | June 30, 2027 | OUELLETTE, SCOT P | reporter.nih.gov |
| HPV ECHO: Increasing the adoption of evidence-based communication strategies for HPV vaccination in rural primary care practices | NIH | National Cancer Institute | 2021 to 2024 | $1,617,347 | August 10, 2020 | April 1, 2025 | CALO, WILLIAM ALEXIS | reporter.nih.gov |
| Translating Evidence into Action: Novel modeling approaches to end the syphilis epidemic in the U.S. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,613,291 | July 11, 2024 | May 31, 2029 | KASAIE, PARASTU | reporter.nih.gov |
| Factors associated with Refractory and Early Recurrent Bacterial Vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,611,815 | February 1, 2024 | December 31, 2028 | TUDDENHAM, SUSAN ANNE | reporter.nih.gov |
| Viral IncRNAs Regulate Host Genomic Transcriptional Programs Associated with Sporadic Alzheimer's Disease | NIH | National Institute on Aging | 2022 to 2025 | $1,606,481 | July 1, 2022 | June 30, 2027 | ROSENFELD, MICHAEL G | reporter.nih.gov |
| Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,595,053 | August 14, 2024 | October 31, 2029 | SPINELLI, MATTHEW A. | reporter.nih.gov |
| Human Papillomavirus Manipulation of Epithelial Differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,591,474 | May 14, 2020 | July 31, 2024 | WHITE, ELIZABETH A | reporter.nih.gov |
| Molecular and cellular mechanisms of HSV-1 assembly and egress | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,590,455 | December 1, 2021 | November 30, 2026 | HOGUE, IAN B | reporter.nih.gov |
| Proteomics of HSV1 Replication | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $1,590,000 | August 15, 2022 | July 31, 2027 | MOHNI, KAREEM N | reporter.nih.gov |
| Identifying drivers of genital inflammation and HIV acquisition in women living in sub-Saharan Africa | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,588,227 | August 2, 2024 | June 30, 2029 | KWON, DOUGLAS | reporter.nih.gov |
| RCT to Evaluate an Implementation Strategy to Increase Optimal Use of HPV Vaccine in Primary Care | NIH | National Cancer Institute | 2021 to 2024 | $1,587,810 | July 2, 2019 | June 30, 2025 | KING, ALLISON A | reporter.nih.gov |
| ALPHA-HERPESVIRUS TRANSPORT IN AXONS | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,586,647 | February 1, 2004 | June 30, 2026 | SMITH, GREGORY ALLAN | reporter.nih.gov |
| Single-cell based diagnostic platform with single-molecular transcriptional response profiling for rapid phenotypic antimicrobial susceptibility testing of gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,577,551 | June 17, 2024 | May 31, 2029 | WANG, TZA-HUEI JEFF | reporter.nih.gov |
| Point-of-care screening test for early cervical cancer detection | NIH | National Cancer Institute | 2021 to 2024 | $1,575,268 | September 22, 2020 | June 30, 2026 | LINNES, JACQUELINE | reporter.nih.gov |
| Comparison of cervical intraepithelial neoplasia 2/3 treatment outcomes with a portable LMIC-adapted thermal ablation device vs. gas-based cryotherapy | NIH | National Cancer Institute | 2021 to 2023 | $1,573,574 | January 12, 2018 | June 30, 2025 | CREMER, MIRIAM | reporter.nih.gov |
| NeoChip for specific and rapid identification of congenital CMV and neonatal HSV infections on minimal sample volume | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $1,568,697 | January 1, 2022 | June 30, 2026 | LAWRENCE, SHELLEY M | reporter.nih.gov |
| Strategies to Prevent HIV Acquisition Among Transgender MSM in the US | NIH | National Institute of Mental Health | 2022 to 2023 | $1,568,065 | August 19, 2022 | January 1, 2024 | REISNER, SARI | reporter.nih.gov |
| Multilevel Peer-to-Peer HPV Vaccination and Wellness Educational Program in School Based Health Centers (PEER) | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $1,559,037 | August 28, 2024 | March 31, 2029 | PETRIK, AMANDA F. | reporter.nih.gov |
| Molecular and cellular basis of epidermodysplasia verruciformis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,557,826 | February 10, 2020 | January 31, 2026 | CASANOVA, JEAN-LAURENT | reporter.nih.gov |
| Vectored delivery of anti-HIV antibodies for mucosal protection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,548,010 | March 14, 2023 | February 28, 2027 | MARTINEZ-NAVIO, JOSE MARIA | reporter.nih.gov |
| Understanding the Host-Microbiome-Therapeutic Triad: Implications for Designing Alternative Intravaginal Delivery Platforms to Treat Bacterial Vaginosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,539,804 | July 5, 2019 | June 30, 2025 | FRIEBOES, HERMANN | reporter.nih.gov |
| Dissecting NF-kB pathway in HPV-associated head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $1,535,027 | March 1, 2023 | December 31, 2027 | YARBROUGH, WENDELL G | reporter.nih.gov |
| Impact of the vaginal microbiome on topical HIV pre-exposure prophylaxis (PrEP) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,533,887 | April 12, 2019 | March 31, 2025 | HEROLD, BETSY C. | reporter.nih.gov |
| Phase 1 Randomized Double-Blind Placebo-Controlled Safety Study of MucoCept-CVN (Lactobacillus jensenii 1153-1666) Administered Vaginally to Healthy Women | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,533,177 | November 22, 2024 | October 31, 2027 | HEMMERLING, ANKE | reporter.nih.gov |
| A seek, test, and treat intervention to reduce Chlamydia trachomatis disparities in youth living in the deep South | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,529,531 | July 1, 2024 | May 31, 2029 | KISSINGER, PATRICIA J | reporter.nih.gov |
| Stress Hormone Regulation of HSV1 and HSV2 in Autonomic and Sensory Neurons | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2025 | $1,525,267 | September 21, 2022 | August 31, 2027 | BERTKE, ANDREA S | reporter.nih.gov |
| Natural History of Chlamydia trachomatis genital tract infection in women | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,520,044 | January 2, 2024 | November 30, 2028 | O'CONNELL, CATHERINE MARY | reporter.nih.gov |
| Structural Studies of Human Papillomavirus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,515,049 | August 13, 2020 | July 31, 2023 | HAFENSTEIN, SUSAN | reporter.nih.gov |
| Immunologic changes associated with three progestin-based contraceptives: characterizing immune profiles over one year and identifying factors that may alter HIV risk | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,507,492 | August 1, 2018 | June 30, 2025 | SMITH, ALICIA K | reporter.nih.gov |
| Renewal: HPV and the DNA Damage Response | NIH | National Cancer Institute | 2022 to 2025 | $1,501,000 | August 1, 2010 | June 30, 2027 | LAIMINS, LAIMONIS A. | reporter.nih.gov |
| Modulation of Alzheimers disease by Herpes simplex virus infection | NIH | National Institute on Aging | 2021 to 2023 | $1,498,473 | September 1, 2019 | May 31, 2025 | DARVAS, MARTIN C | reporter.nih.gov |
| Chromatin dynamics in the regulation of herpes simplex virus 1 gene expression. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,498,123 | May 11, 2020 | April 30, 2025 | SCHANG, LUIS M. | reporter.nih.gov |
| Meningococcal and gonococcal vaccine to prevent invasive disease and carriage | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,494,920 | July 5, 2000 | January 31, 2025 | MOE, GREGORY ROBERT | reporter.nih.gov |
| SBIR Topic 108: Development of Rapid Molecular Assay for Point of Care Detection of Treponema Pallidum | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $1,488,107 | September 3, 2024 | September 2, 2027 | COCKRELL, LISA | reporter.nih.gov |
| Role of insulin-like growth factor binding proteins in the pathogenesis of herpes stromal keratitis. | NIH | National Eye Institute | 2021 to 2024 | $1,486,332 | August 1, 2020 | July 31, 2025 | SUVAS, SUSMIT | reporter.nih.gov |
| Molecular Genetics of HSV Reactivation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,482,291 | July 1, 2001 | February 28, 2025 | BLOOM, DAVID C. | reporter.nih.gov |
| The role of plasmacytoid dendritic cells in corneal immunity | NIH | National Eye Institute | 2023 to 2025 | $1,482,095 | September 1, 2023 | June 30, 2027 | HAMRAH, PEDRAM | reporter.nih.gov |
| HPV genomic structure in cervical cancer radiation response and recurrence detection | NIH | National Cancer Institute | 2023 to 2025 | $1,478,822 | May 1, 2023 | April 30, 2028 | ZHANG, JIN | reporter.nih.gov |
| A Randomized Controlled Trial of an HPV Vaccine Intervention for Young Sexual Minority Men | NIH | National Cancer Institute | 2021 to 2023 | $1,471,557 | April 1, 2018 | March 21, 2025 | REITER, PAUL L | reporter.nih.gov |
| Technology Enhanced Community Health Nursing to Reduce Recurrent STIs after PID | NIH | National Institute of Nursing Research | 2021 to 2023 | $1,458,130 | April 1, 2012 | March 31, 2025 | TRENT, MARIA E. | reporter.nih.gov |
| Actions for Collaborative Community Engaged Strategies for HPV (ACCESS-HPV) | NIH | National Cancer Institute | 2023 to 2025 | $1,457,658 | September 22, 2022 | August 31, 2027 | IWELUNMOR, JULIET | reporter.nih.gov |
| Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub) | NIH | National Cancer Institute | 2024 to 2025 | $1,451,327 | September 20, 2022 | May 31, 2027 | WILKIN, TIMOTHY J. | reporter.nih.gov |
| Harnessing Aurora kinase inhibition‐induced cell death to enhance immunotherapy in HPV‐driven cancers | NIH | National Cancer Institute | 2021 to 2024 | $1,448,950 | April 1, 2020 | March 31, 2025 | JOHNSON, FAYE | reporter.nih.gov |
| The impact of vaginal washing on cervical inflammation: a randomized controlled trial of women from sub-Saharan Africa at high risk for HIV acquisition. | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,448,617 | September 16, 2024 | June 30, 2029 | SABO, MICHELLE CATHERINE | reporter.nih.gov |
| RepurPosed AntiretrOviraL ThErapieS to EliminAte Cervical Cancer (POLESA Trial) | NIH | National Cancer Institute | 2023 to 2025 | $1,440,319 | August 1, 2023 | July 31, 2028 | PINDER, LEEYA F | reporter.nih.gov |
| Extracellular Matrix Adhesins of Treponema pallidum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,424,874 | December 19, 2023 | October 31, 2028 | CAMERON, CAROLINE E | reporter.nih.gov |
| Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice (PREDICT) | NIH | National Cancer Institute | 2024 to 2025 | $1,423,644 | June 10, 2024 | May 31, 2026 | HAAS, JENNIFER S | reporter.nih.gov |
| Linkages between HIV/STI prevention and syndemic behaviors in high risk youth: Common factors and unique pathways | NIH | National Heart, Lung, and Blood Institute | 2024 to 2025 | $1,419,911 | September 5, 2024 | July 31, 2028 | FELDSTEIN EWING, SARAH W. | reporter.nih.gov |
| Enhancing Primary Care Office Workflow to Prevent Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,417,156 | December 1, 2022 | May 31, 2028 | RAND, CYNTHIA M | reporter.nih.gov |
| Partnership for advancing cervical cancer prevention in women living with HIV (CASCADE - Research Hub) | NIH | National Cancer Institute | 2022 to 2024 | $1,416,601 | September 20, 2022 | July 14, 2024 | WILKIN, TIMOTHY J. | reporter.nih.gov |
| Point of Care Detection of HPV and P16 in Saliva | NIH | National Institute of Dental & Craniofacial Research | 2025 | $1,414,853 | August 8, 2025 | July 31, 2027 | KHOSRAVI-FAR, ROYA | reporter.nih.gov |
| Sexual health behaviors among US adolescents and young adults | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,414,045 | September 17, 2024 | May 31, 2028 | NELSON, KIMBERLY M | reporter.nih.gov |
| Role of type 1 IFN in eye infection | NIH | National Eye Institute | 2023 to 2025 | $1,411,629 | August 1, 2023 | February 28, 2027 | GHIASI, HOMAYON | reporter.nih.gov |
| Function and regulation of the intrinsic antibiotic resistome of Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,396,446 | July 24, 2019 | June 30, 2025 | SHAFER, WILLIAM MAURICE | reporter.nih.gov |
| Stress-Mediated Regulation of HSV-1 Reactivation from Latency | NIH | National Institute of Neurological Disorders and Stroke | 2021 to 2024 | $1,395,693 | April 1, 2020 | January 31, 2026 | JONES, CLINTON J | reporter.nih.gov |
| Secondary Cervical Cancer Prevention of Vulnerable Women with HPV and HIV Co-infection in India | NIH | National Cancer Institute | 2023 to 2025 | $1,393,110 | August 1, 2023 | July 31, 2029 | NYAMATHI, ADELINE M | reporter.nih.gov |
| Mouse Model of Human Papillomavirus Pathogenesis | NIH | National Cancer Institute | 2021 to 2023 | $1,386,914 | April 1, 2019 | March 31, 2025 | MUNGER, KARL | reporter.nih.gov |
| Integrating expedited partner STI therapy during PrEP delivery for young women | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,386,835 | September 22, 2020 | June 30, 2023 | BALKUS, JENNIFER ELLEN | reporter.nih.gov |
| HPV-related Oropharyngeal Cancer Screening and Monitoring through Remote Self-Sampling | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,386,022 | April 19, 2024 | January 31, 2029 | STURGIS, ERICH MADISON | reporter.nih.gov |
| Addressing Cervical Cancer Disparities Among People Experiencing Homelessness | NIH | National Institute on Minority Health and Health Disparities | 2023 | $1,382,625 | September 1, 2023 | June 30, 2026 | RODRIGUEZ, NATALIA MARIA | reporter.nih.gov |
| Regulation of HSV latency by Polycomb Silencing | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,380,341 | June 7, 2024 | April 30, 2029 | CLIFFE, ANNA RUTH | reporter.nih.gov |
| Intra-tumoral neurons contribute to head and neck cancer pain | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $1,375,081 | April 1, 2023 | March 31, 2028 | VERMEER, PAOLA DRAPKIN | reporter.nih.gov |
| Interferon-inducible cell-intrinsic host defense against Chlamydia trachomatis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,373,301 | May 15, 2013 | January 31, 2024 | COERS, JOERN | reporter.nih.gov |
| Onco-immunologic factors contributing to OPSCC among people living with HIV | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,370,063 | September 20, 2024 | June 30, 2029 | BANSAL, ANJU | reporter.nih.gov |
| ROLES OF HOST FACTORS IN VIRAL REPLICATION COUPLED PROCESSES | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,369,650 | February 7, 2022 | January 31, 2027 | DEMBOWSKI, JILL ANN | reporter.nih.gov |
| Cue-101 and TCR-T cell Combinatorial Strategy for HPV+ Head and Neck Cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,366,537 | March 1, 2024 | February 28, 2029 | PAI, SARA ISABEL | reporter.nih.gov |
| Viral disruption of host transcriptome integrity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,364,911 | February 1, 2023 | January 31, 2028 | WILSON, ANGUS C | reporter.nih.gov |
| Mechanisms underlying recurrent bacterial vaginosis and HIV risk A Multidisciplinary approach | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,364,663 | August 20, 2018 | July 31, 2025 | ALCAIDE, MARIA LUISA | reporter.nih.gov |
| Self-Testing for Cervical Cancer in Priority Populations: the STEP-2 Trial | NIH | National Cancer Institute | 2024 to 2025 | $1,356,980 | May 15, 2024 | April 30, 2026 | WINER, RACHEL L. | reporter.nih.gov |
| Synthesis of Therapeutic Agents for Treatment of Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,356,473 | February 16, 2015 | February 15, 2019 | MIDDLETON, MARK | reporter.nih.gov |
| CTFC Mediated HSV-1 Gene Expression in Latency and Reactivation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,346,197 | November 15, 2018 | October 31, 2024 | NEUMANN, DONNA M | reporter.nih.gov |
| Automated Visual Evaluation for Cervical Cancer Screening in HIV-positive Women | NIH | National Cancer Institute | 2021 to 2024 | $1,331,744 | June 1, 2020 | May 31, 2026 | SAIDU, RAKIYA SAIDU | reporter.nih.gov |
| Interplay between nuclear stress responses and herpesvirus latency | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,329,990 | November 8, 2023 | October 31, 2028 | WILSON, ANGUS C | reporter.nih.gov |
| Strategies to Prevent HIV Acquisition for At-Risk Men in the US | NIH | National Institute of Mental Health | 2024 to 2025 | $1,328,950 | May 15, 2024 | October 31, 2027 | REISNER, SARI | reporter.nih.gov |
| Evaluating the intersection between sexually transmitted infections, inflammation and reproductive success | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,323,085 | March 1, 2020 | August 31, 2024 | TAYLOR, BRANDIE DEPAOLI | reporter.nih.gov |
| #TranscendentHealth - Adapting an LGB+ inclusive teen pregnancy prevention program for transgender boys | NIH | National Institute of Nursing Research | 2023 to 2024 | $1,319,024 | September 14, 2023 | June 30, 2027 | YBARRA, MICHELE L. | reporter.nih.gov |
| Reducing maternal and child health disparities through point-of-care STI testing in underserved populations (MATCH-POINT) | NIH | National Institute on Minority Health and Health Disparities | 2025 | $1,318,470 | September 19, 2025 | June 30, 2027 | WALL, KRISTIN MARIE | reporter.nih.gov |
| Role of the YAP1-LATS2 negative feedback loop in cervical carcinogenesis | NIH | National Cancer Institute | 2023 to 2025 | $1,315,399 | April 1, 2023 | March 31, 2028 | WANG, CHENG | reporter.nih.gov |
| Herpes simplex virus egress from neurons into axons mediated by HSV membrane proteins gE/gI and US9 and axonal transport by kinesin motors. | NIH | National Eye Institute | 2021 to 2023 | $1,314,062 | July 1, 1998 | October 31, 2025 | JOHNSON, DAVID C. | reporter.nih.gov |
| Next Generation of HPV and Cervical Cancer Research in HIV+ Women | NIH | National Cancer Institute | 2021 to 2022 | $1,311,548 | July 11, 2018 | June 30, 2024 | STRICKLER, HOWARD D | reporter.nih.gov |
| Mechanistic connection between HPV-specific TCRs and therapeutic responses to ICI in HPV+ HNSCC | NIH | National Cancer Institute | 2024 to 2025 | $1,310,488 | April 1, 2024 | March 31, 2029 | WANG, JING HONG | reporter.nih.gov |
| Tissue Regulatory T Cells in Mucosal Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,309,591 | November 7, 2018 | October 31, 2024 | LUND, JENNIFER M | reporter.nih.gov |
| The Collaborative Care PrTNER (Prevention, Treatment, Navigation, Engagement, Resource) Project | NIH | National Institute on Drug Abuse | 2024 to 2025 | $1,305,781 | September 15, 2023 | June 30, 2029 | SANDERS, RENATA ARRINGTON | reporter.nih.gov |
| PrEP My Way: A hybrid type 1 clinical effectiveness-implementation trial to promote PrEP persistence among young Kenyan women | NIH | National Institute of Mental Health | 2024 to 2025 | $1,302,855 | July 23, 2024 | April 30, 2029 | HABERER, JESSICA ELIZABETH | reporter.nih.gov |
| A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,300,723 | December 17, 2024 | August 31, 2027 | NG, RAINER | reporter.nih.gov |
| Repurposing and reformulation of adefovir dipivoxil for improved topical treatment of herpes simplex virus infection of the eye | NIH | National Eye Institute | 2024 to 2025 | $1,297,477 | July 1, 2024 | June 30, 2028 | DATE, ABHIJIT A | reporter.nih.gov |
| Mapping Protein Interaction Networks Essential for Gonococcal Pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,291,466 | May 6, 2021 | August 31, 2022 | EMILI, ANDREW | reporter.nih.gov |
| The role of antiretroviral therapy in susceptibility to oral human papillomavirus (HPV) infection | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,275,805 | September 16, 2024 | June 30, 2029 | CAMERON, JENNIFER ERIN | reporter.nih.gov |
| Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,274,805 | August 3, 2023 | December 31, 2026 | GERSHBURG, EDWARD | reporter.nih.gov |
| E7 TCR-T cell therapy for HPV-associated cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,269,979 | August 1, 2024 | July 31, 2028 | HINRICHS, CHRISTIAN | reporter.nih.gov |
| Integrated Female Sexually Transmitted Infection Testing for HIV Epidemic Control through PrEP: The IN-STEP study | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,258,067 | March 13, 2024 | January 31, 2029 | GRABOWSKI, MARY KATHRYN | reporter.nih.gov |
| Utilization of cervical cancer prevention tools and role of high-risk HPV type in the persistent cervical cancer disparities experienced by American Indian/Alaska Native women | NIH | National Cancer Institute | 2021 to 2025 | $1,257,642 | August 1, 2021 | July 31, 2026 | BRUEGL, AMANDA S | reporter.nih.gov |
| Structural Studies of Human Papillomavirus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,255,920 | August 13, 2020 | July 31, 2025 | HAFENSTEIN, SUSAN | reporter.nih.gov |
| Regulation of the Human Papillomavirus Life Cycle by the Long Noncoding RNA DINO | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,255,278 | June 1, 2023 | May 31, 2028 | MUNGER, KARL | reporter.nih.gov |
| Epidemiologic Impact of HPV Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,253,203 | January 18, 2013 | July 31, 2025 | DING, LILI | reporter.nih.gov |
| A hybrid type III effectiveness-implementation, pragmatic intervention trial for cervical cancer screen and treat in Mozambique | NIH | National Cancer Institute | 2024 to 2025 | $1,251,158 | September 1, 2024 | August 31, 2029 | MOON, D. TROY | reporter.nih.gov |
| Sexual Health Empowerment for Jail-Involved Women's Health Literacy and Prevention | NIH | National Cancer Institute | 2021 to 2023 | $1,249,946 | April 23, 2014 | March 31, 2025 | WICKLIFFE, JOI | reporter.nih.gov |
| Perceived Norms About Alcohol Use and HIV/STI Prevention among Adolescents and Young Adults in Rural Uganda | NIH | National Institute on Alcohol Abuse and Alcoholism | 2024 to 2025 | $1,248,062 | September 20, 2024 | August 31, 2029 | PERKINS, JESSICA M | reporter.nih.gov |
| Interplay between hypoxia and oxidative phosphorylation in herpes stromal keratitis | NIH | National Eye Institute | 2021 to 2023 | $1,242,271 | March 1, 2019 | February 28, 2025 | SUVAS, SUSMIT | reporter.nih.gov |
| Interplay between the cellular DNA damage response and the HPV life cycle | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,237,684 | May 18, 2023 | April 30, 2028 | MOODY, CARY A | reporter.nih.gov |
| The role of asymmetric protein dimethylation during the human papillomavirus lifecycle | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,227,574 | June 7, 2022 | May 31, 2028 | VAN DOORSLAER, KOENRAAD | reporter.nih.gov |
| Improving the Detection of STIs in the Pediatric Emergency Department: A Pragmatic Trial | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2022 | $1,225,686 | September 1, 2018 | July 31, 2025 | GOYAL, MONIKA KUMARI | reporter.nih.gov |
| The A-HACK Project: Addressing Heavy Alcohol Consumption with Kudzu | NIH | National Institute on Alcohol Abuse and Alcoholism | 2021 to 2022 | $1,223,647 | September 20, 2018 | July 31, 2024 | SANTOS, GLENN-MILO | reporter.nih.gov |
| Technology development for point-of-care detection and antimicrobial susceptibility testing of Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $1,220,681 | August 22, 2018 | July 31, 2024 | WANG, TZA-HUEI JEFF | reporter.nih.gov |
| Human placental biodisposition of novel antiherpesviral drugs, amenamevir and pritelivir, using ex vivo and in vitro experimental models | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2024 | $1,218,420 | August 11, 2022 | July 31, 2025 | BRYANT, VALENTINA FOKINA | reporter.nih.gov |
| Improving perinatal outcomes among Kenyan pregnant women affected by HIV with an integrated STI testing model | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $1,217,836 | March 2, 1997 | January 31, 2029 | PINTYE, JILLIAN | reporter.nih.gov |
| In This toGether: Testing a population-based text messaging-based HIV prevention program for young adults across Uganda | NIH | National Institute of Mental Health | 2024 to 2025 | $1,210,902 | June 12, 2024 | January 31, 2029 | YBARRA, MICHELE L. | reporter.nih.gov |
| DECON: A sustained topical delivery platform to treat ocular inflammation | NIH | National Eye Institute | 2023 to 2025 | $1,210,082 | September 30, 2023 | April 30, 2028 | YADAVALLI, TEJABHIRAM | reporter.nih.gov |
| Exploring mechanisms of therapeutic demethylation effects in HPV-associated head and neck cancer | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2023 | $1,209,988 | June 1, 2019 | July 31, 2024 | YARBROUGH, WENDELL G | reporter.nih.gov |
| Mucosal Chemokines and CD8+ T Cell Immunity to Genital Herpes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,202,999 | August 15, 2019 | July 31, 2025 | BENMOHAMED, LBACHIR | reporter.nih.gov |
| Defining the Role of HPV Integration Structures in HNSCC Molecular Heterogeneity | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,198,531 | August 1, 2024 | April 30, 2029 | BRENNER, JOHN CHADWICK | reporter.nih.gov |
| Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal Carcinoma | NIH | National Cancer Institute | 2021 to 2023 | $1,196,682 | March 8, 2018 | February 28, 2025 | KOYFMAN, SHLOMO | reporter.nih.gov |
| Development of a Chlamydia trachomatis Vaccine in an Outbred Pre-exposed Swine Animal Model | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,192,354 | June 16, 2021 | December 31, 2022 | KAESER, TOBIAS E | reporter.nih.gov |
| Functional relevance of C. trachomatis trp operon polymorphism | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,191,432 | August 19, 2024 | June 30, 2029 | CARABEO, REY A | reporter.nih.gov |
| Dynamic interplay between IL-36 and IL-1 in inflammation and infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,188,750 | June 1, 2023 | May 31, 2028 | JENSEN, LISELOTTE E | reporter.nih.gov |
| Next generation ultra-long acting antiretroviral formulations for HIV treatment and prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,188,509 | September 24, 2018 | June 15, 2023 | GARCIA-MARTINEZ, J. VICTOR | reporter.nih.gov |
| Leveraging Project ECHO for improved cervical cancer screening in Ethiopia: An implementation study of integrated HPV selfsampling in HIV care centers | NIH | National Cancer Institute | 2024 to 2025 | $1,181,416 | August 15, 2024 | July 31, 2029 | LOTT, BREANNE | reporter.nih.gov |
| Kyaterekera Project: A Combination Intervention Addressing Sexual Risk-Taking Behaviors Among Vulnerable Women in Uganda | NIH | National Institute of Mental Health | 2021 to 2022 | $1,179,195 | August 24, 2018 | May 31, 2024 | SSEWAMALA, FRED M | reporter.nih.gov |
| How chlamydia generates cytoskeletal scaffolds and their role during infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,170,000 | January 22, 2019 | December 31, 2024 | PAUMET, FABIENNE MICHELLE | reporter.nih.gov |
| Technology-Based Intervention For Reducing Sexually Transmitted Infections and Substance Use During Pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2023 | $1,164,888 | August 28, 2018 | May 31, 2025 | TZILOS WERNETTE, GOLFO K | reporter.nih.gov |
| Botswana CASCADE Clinical Trials Site | NIH | National Cancer Institute | 2022 to 2025 | $1,163,675 | September 5, 2022 | May 31, 2027 | DRYDEN-PETERSON, SCOTT | reporter.nih.gov |
| Molecular Markers for Tumors Associated with Extrachromosomal HPV | NIH | National Cancer Institute | 2024 to 2025 | $1,161,888 | March 5, 2024 | February 28, 2029 | OJESINA, AKINYEMI IFEDAPO | reporter.nih.gov |
| Characterize longitudinal events of oral high-risk human papillomavirus to alter risk for oropharyngeal cancer (CLEAR) | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $1,161,040 | September 1, 2024 | May 31, 2029 | NOWAK, REBECCA G. | reporter.nih.gov |
| A couples-based approach to HIV prevention for transgender women and their male partners | NIH | National Institute of Mental Health | 2021 to 2022 | $1,158,942 | July 15, 2018 | March 20, 2025 | GAMAREL, KRISTI E | reporter.nih.gov |
| Implementation of a Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors receiving Follow-Up Care in Pediatric Oncology Practices: A Cluster-Randomized Trial | NIH | National Cancer Institute | 2023 to 2024 | $1,158,790 | September 18, 2020 | August 31, 2025 | LANDIER, WENDY | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Family Health International | Durham, NC | 2 | $213.8 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 8 | $86.7 million | 0 | $0 |
| University of Washington | Seattle, WA | 56 | $84.4 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 28 | $78.6 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 17 | $65 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 44 | $57.6 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 31 | $56.4 million | 0 | $0 |
| Emory University | Atlanta, GA | 30 | $43.6 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 35 | $40.7 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 9 | $36 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 1 | $35.1 million | 0 | $0 |
| Fundacion Inciensa | San Jose | 2 | $32.6 million | 0 | $0 |
| Yale University | New Haven, CT | 11 | $30.5 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 13 | $30.4 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 25 | $27.7 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 18 | $27.4 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 18 | $26.4 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 20 | $26.2 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 18 | $24.3 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 16 | $22.9 million | 0 | $0 |
| Saint Louis University | Saint Louis, MO | 3 | $21.8 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 15 | $21.6 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 17 | $19.1 million | 0 | $0 |
| University of California at Davis | Davis, CA | 4 | $19 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 16 | $17.7 million | 0 | $0 |
| Washington University | Saint Louis, MO | 19 | $17.4 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 14 | $17.3 million | 0 | $0 |
| Fred Hutchinson Cancer Research Center | Seattle, WA | 10 | $17.3 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 10 | $16.9 million | 0 | $0 |
| Duke University | Durham, NC | 16 | $16.3 million | 0 | $0 |
| University of Connecticut SCH of Med/dnt | Farmington, CT | 9 | $15.9 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 13 | $14.4 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 9 | $14.2 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 8 | $14.1 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 8 | $13.5 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 24 | $13.3 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 14 | $13.2 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 15 | $12.7 million | 0 | $0 |
| Public Health Foundation Enterprises | City Of Industry, CA | 2 | $11.5 million | 0 | $0 |
| Children's Hospital of Los Angeles | Los Angeles, CA | 1 | $11.5 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 6 | $11.3 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 7 | $11.1 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 17 | $11 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 13 | $10.9 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 13 | $10.3 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 16 | $10.3 million | 0 | $0 |
| Chiang Mai University | Chiang Mai | 1 | $10.1 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 9 | $9.6 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 8 | $9.5 million | 0 | $0 |
| Arizona State University | Scottsdale, AZ | 6 | $9.4 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 10 | $9.3 million | 0 | $0 |
| Research Triangle Institute | Research Triangle Park, NC | 4 | $8.9 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 6 | $8.8 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 5 | $8.7 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 6 | $8.6 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 5 | $8.2 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 4 | $8.1 million | 0 | $0 |
| University of Florida | Gainesville, FL | 9 | $8.1 million | 0 | $0 |
| Advanced Bioscience Laboratories, Inc. | Kensington, MD | 1 | $8.1 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 6 | $7.5 million | 0 | $0 |
| Center for Innovative Public Health Research | San Clemente, CA | 4 | $7.3 million | 0 | $0 |
| Population Council | New York, NY | 2 | $7.2 million | 0 | $0 |
| Therapyx, Inc. | Buffalo, NY | 4 | $7.2 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 7 | $7 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 5 | $6.9 million | 0 | $0 |
| Rockefeller University | New York, NY | 4 | $6.8 million | 0 | $0 |
| Tufts Medical Center | Boston, MA | 3 | $6.8 million | 0 | $0 |
| Hunter College | New York, NY | 4 | $6.7 million | 0 | $0 |
| Aurum Institute NPC | Parktown, Johannesburg | 1 | $6.7 million | 0 | $0 |
| Pennsylvania State Univ Hershey Med CTR | Hershey, PA | 7 | $6.7 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 6 | $6.6 million | 0 | $0 |
| Intravacc B.V. | Bilthoven | 1 | $6.6 million | 0 | $0 |
| Rush University Medical Center | Chicago, IL | 4 | $6.6 million | 0 | $0 |
| Stellenbosch University | Stellenbosch | 1 | $6.5 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 4 | $6.5 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 6 | $6.5 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 3 | $6.2 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 5 | $6.1 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 5 | $5.9 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 5 | $5.9 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 3 | $5.5 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 5 | $5.5 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 4 | $5.5 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 4 | $5.5 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 8 | $5.4 million | 0 | $0 |
| Montana State University | Bozeman, MT | 3 | $5.3 million | 0 | $0 |
| Klein Buendel, Inc. | Golden, CO | 1 | $5.2 million | 0 | $0 |
| San Diego State University Foundation | San Diego, CA | 2 | $5.2 million | 0 | $0 |
| Florida International University | Miami, FL | 4 | $5.2 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 10 | $5.1 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 2 | $5 million | 0 | $0 |
| University of Victoria | Victoria | 3 | $5 million | 0 | $0 |
| Cornell University | Ithaca, NY | 3 | $4.9 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 3 | $4.9 million | 0 | $0 |
| Mucommune, LLC | Morrisville, NC | 9 | $4.9 million | 0 | $0 |
| Wayne State University | Detroit, MI | 4 | $4.9 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 6 | $4.9 million | 0 | $0 |
| Lifegene-Biomarks, Inc. | San Juan, PR | 3 | $4.9 million | 0 | $0 |
| Univ of Arkansas for Med Scis | Little Rock, AR | 3 | $4.7 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 2 | $4.6 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 614 | $394,570,340 | 0 | $0 |
| 2024 | 670 | $419,124,968 | 0 | $0 |
| 2023 | 636 | $397,237,630 | 0 | $0 |
| 2022 | 603 | $402,113,363 | 0 | $0 |
| 2021 | 603 | $481,856,491 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 6 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 3 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 2 awards here | |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required) | PA-24-175 | NIH | May 7, 2027 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 589 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 589 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 589 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 589 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 589 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 589 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 589 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.